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The vast majority of adult mammalian cardiomyocytes are terminally differentiated and 
therefore do not proliferate under physiological conditions. The heart still retains its 
capability to respond to environmental demands, and cardiomyocytes can grow in 
reaction to various physiological or pathological stimuli. Primary triggering events for 
cardiac hypertrophy are mechanical stress and neurohumoral stimulation, which induce 
various cellular responses including changes in gene expression, protein synthesis and 
cell metabolism, leading to the development and progression of cardiac hypertrophy 
(Francis et al., 1993; Lyon et al., 2015; Maillet et al., 2013). Growth of the body, 
pregnancy or physical exercise induces physiological enlargement of the heart, which 
occurs through hypertrophy of the individual cardiomyocytes, and is characterized by 
normal or enhanced contractility coupled with normal architecture and organization of 
cardiac structure (Weeks & McMullen, 2011). Therefore, physiological myocardial 
hypertrophy is generally not considered to be a risk factor for heart failure. In contrast, 
pathological cardiac hypertrophy is associated with hemodynamic overload, injury and 
loss of cardiomyocytes resulting in cardiac remodeling (Sano et al., 2007; Shimizu et 
al., 2010). The occurring pathophysiological changes include, but are not limited to 
metabolic derangement, altered calcium handling, inflammation, cell death and fibrosis. 
Although pathological and physiological myocardial hypertrophy might appear to be 
similar phenotypically, it has long been known that they differ fundamentally in the 
signaling pathways that drive their development (Shimizu & Minamino, 2016). 
Mortality share of cardiovascular diseases has continuously been increasing for decades, 
now accounting for approximately 40% of deaths caused by non-communicable 
diseases (Figure 1.). Long standing pathological hypertrophy is a major underlying 
cause of heart failure (HF). Pressure overload, a highly prevalent cause of pathological 
myocardial hypertrophy induces adverse remodeling of the left ventricle (LV) that can 
result in HF with preserved ejection fraction (HFpEF). HFpEF is increasingly 
investigated, as its burden is similar to HF with reduced ejection fraction [HFrEF, 
(Kelly et al., 2015)]. Although effective pharmacological and device therapies have 
been developed to decrease the burden of HFrEF (Emdin et al., 2015), clinical trials 




Kelly et al., 2015). Therefore, new therapeutic approaches might be feasible in 
addressing the growing public health burden of HFpEF. 
A feasible option to improve outcomes of HFpEF patients might be to target and alter 
molecular pathways currently not involved in pharmacological therapies. Such an 
interesting target is the second messenger cyclic GMP (cGMP) and its downstream 
signaling in cardiomyocytes. cGMP generated in response to nitric oxide (NO) 
production is an important intracellular regulator of many physiological and 
pathophysiological processes in the cardiovascular system, including cardiac 
remodeling (Tsai & Kass, 2009). It has previously been shown that elevated cytosolic 
Figure 1. Leading causes of cardiovascular mortality worldwide and their change 
between 2006 and 2016 
For the first time in human history, non-communicable diseases cause more deaths every 
year than epidemics worldwide, approximately 40% of which deaths are of cardiovascular 
origin. As such, cardiovascular conditions are the leading causes of mortality on our globe. 
This figure details the most frequent cardiovascular diseases resulting in death, showing the 
annual number of deaths and the percent change of death rate in 2016 compared with 2006 
(GBD 2016 Mortality Collaborators, 2017). 
Afib – atrial fibrillation; CMs – cardiomyopathies; CVD – cerebrovascular disease; HHD – 




levels of cGMP originated either from blockade of its degrading enzyme, 
phosphodiesterase type 5 (PDE-5) (Takimoto et al., 2005a) or from increasing its 
production by stimulating or activating its producing enzyme, soluble guanylate cyclase 
(sGC) (Fraccarollo et al., 2014; Frankenreiter et al., 2018; Korkmaz et al., 2009) 
preserved myocardial structure and function in experimental ischemia-reperfusion 
models. Therefore, elevating myocardial cGMP levels might prove to be an effective 
new method of preventing the development of pathological myocardial hypertrophy. A 
new group of drugs named sGC activators has been developed in order to counteract the 
impairment of the NO-cGMP pathway (Evgenov et al., 2006). Cinaciguat (BAY 58-
2667) is the most potent member of the sGC activators developed to this date (Stasch et 
al., 2002), which is capable of activating even inactive forms of sGC (Schmidt et al., 
2009). 
In the following brief review of the literature, I will summarize our knowledge of 
physiological and pathological myocardial hypertrophy, redox and NO/cGMP signaling 
in health and disease, as well as the concept of sGC activation, a novel therapeutic 





2.1. Physiological myocardial hypertrophy 
2.1.1. Cardiac structural changes in physiological myocardial hypertrophy  
Physiological myocardial hypertrophy occurs naturally during growth or pregnancy, and 
is also the response of the heart to regular exercise. The diameter of human 
cardiomyocytes increase approximately 3-fold during growth from infancy to 
adulthood, and there is a linear relationship between body weight and cardiac weight. 
Cardiomyocytes in an adult heart retain their ability to increase the amount of 
contractile proteins within them in response to moderate mechanical stress, and the 
mode of sarcomere addition, discussed below in more detail, will define the final 
hypertrophic phenotype. Importantly, adverse events characteristic to remodeling such 
as fibrosis do not develop during this type of growth, resulting in maintained cardiac 
structure, function, and metabolism (Gibb & Hill, 2018). 
Exercise is associated with a similar enlargement of the heart that is generally thought to 
be harmless and even beneficial in healthy people. Different types of exercise, however, 
affect cardiac enlargement differently, as the heart conforms the type of hemodynamic 
load imposed on the cardiovascular system (Maillet et al., 2013). Dynamic sports, such 
as running or swimming, induce volume overload of the heart since there is an intensive 
dilatation of the skeletal muscle vasculature, leading to increased venous return to the 
heart (Pluim et al., 2000). Thus, athletes trained in sports requiring sustained isotonic 
movement develop eccentric cardiac hypertrophy that is characterized by chamber 
enlargement and proportionate thickening of the ventricular walls (Figure 2.). In this 
setting, cardiomyocytes grow both in length and width. In contrast, sports involving 
development of muscular tension against increased resistance, such as weightlifting or 
wrestling, induce pressure overload of the heart. As such, static exercise leads to 
concentric LV hypertrophy (LVH), where wall thickness increases without 
proportionate dilation of the LV, leading to decreased LV cavity dimensions [Figure 2.; 
(Bernardo et al., 2010)]. Cardiomyocytes usually increase in thickness more than in 
length during concentric hypertrophy (Heineke & Molkentin, 2006; Selby et al., 2011). 
There are also sports that combine dynamic and static components, such as cycling or 
rowing, where endurance training is completed against elevated resistance. This 




increase in wall thickness (Barbier et al., 2006; Pelliccia et al., 1991; Pluim et al., 
2000). Therefore, it is now widely accepted that the phenotype of hypertrophy resulting 
from any type of exercise is dependent upon the ratio of the static and dynamic 
components of that particular exercise (Mitchell et al., 2005). Furthermore, factors such 
as gender, ethnicity or age also influence the final observable phenotype (Colombo & 
Finocchiaro, 2018; Pavlik et al., 2013). It must also be noted here, however, that 
Figure 2. The proposed two extremes of cardiac wall and chamber alterations in 
physiological myocardial hypertrophy 
Classical view of cardiac hypertrophy in response to exercise was dichotomous: dynamic 
types of exercise were thought to induce eccentric hypertrophy due to the volume 
overloading of the heart, while static sports would induce pressure overload of the left 
ventricle, therefore causing concentric hypertrophy. More recent investigations highlighted 
that the final phenotype of hypertrophy is dependent upon the ratio of dynamic and static 
components of the exercise, and that it is more of a continuum than two easily separable 




extreme exercise associated with competitive sport might result in a maladaptive 
hypertrophic response, which is still a diagnostic challenge for clinicians to differentiate 
from innocuous changes based on observation of phenotypic deteriorations alone (De 
Innocentiis et al., 2018; Gabrielli et al., 2018). 
In contrast to the LV, response of the right ventricle (RV) to exercise training was not 
investigated in detail until relatively recently, mostly because of its more complex 
geometry and location inside the chest. Echocardiographic investigation of the RV is 
difficult at best, and many times accurate measurements are not possible due to 
anatomical reasons. The development of cardiac magnetic resonance imaging (cMRI) 
allowed for a more complex and accurate characterization of RV structural and 
functional changes following exercise. Similarly to LV alterations, RV volume, mass 
and stroke volume have all been observed to increase in athletes (Scharhag et al., 2002). 
Contrary to the LV, however, RV hypertrophy and dilatation seem to occur only 
following dynamic training, while static exercise does not influence RV dimensions 
(Eijsvogels et al., 2016; Weiner & Baggish, 2012). A possible downside of endurance 
training might be that atrial enlargement in athletes predisposes them to an increased 
risk of atrial fibrillation (D'Ascenzi et al., 2015; Wilhelm et al., 2012). 
2.1.2. Functional changes associated with exercise training 
While structural changes of the LV have been described somewhat consistently, 
functional alterations are not so well characterized. This discrepancy stems from the fact 
that the overwhelming majority of studies investigating the athlete’s heart phenomenon 
have utilized conventional echocardiography to describe cardiac function (Utomi et al., 
2013), and while this modality is optimal for the investigation of structural alterations, it 
is not as reliable when it comes to functional parameters. The value of both fractional 
shortening (FS) and ejection fraction (EF), which are the most common systolic indices 
that have been used to evaluate cardiac function in athletes, is dependent upon multiple 
factors including loading conditions and heart rate. cMRI, although less influenced by 
anatomical variations and thus capable of providing better spatial resolution, can only 
measure these parameters as well. Meta-analyses based on studies utilizing these non-
invasive modalities concluded that systolic function is preserved or somewhat enhanced 
in athletes compared with sedentary controls during resting conditions (Fagard, 2003; 




significant effect of study-to-study heterogeneity was noted (Utomi et al., 2013). EF and 
FS investigated in these studies reflect chamber mechanics, which, especially in rest, 
might leave subtle, but important differences unnoticed. Investigation of intrinsic 
myocardial mechanics therefore might provide a better insight into the real functional 
alterations characterizing exercise-induced hypertrophy (Simsek et al., 2013). Our 
research group has published a more detailed characterization of athlete’s heart in a rat 
model (Radovits et al., 2013), utilizing the invasive pressure-volume (P-V) analysis that 
is capable of providing load independent indices of both systolic and diastolic function. 
Athlete’s heart in humans, however, cannot ethically be investigated with an invasive 
method, given its generally harmless nature. Development of the novel 
echocardiographic imaging modes tissue Doppler and speckle-tracking imaging allows 
for a more detailed and more accurate assessment of LV systolic function that correlates 
well with invasive measurements (Kovacs et al., 2015). The results of studies 
implementing these modalities provided similar data, i.e. normal or supernormal cardiac 
systolic and diastolic function was found in athletes (Beaumont et al., 2017; D'Andrea 
et al., 2006; Kovacs et al., 2014; Richand et al., 2007). 
Despite its clinical importance, LV diastolic function is an entity that has been difficult 
to assess (George et al., 2010). The gold standard measure of LV active relaxation, τ, is 
the time constant of isovolumic pressure decline in the LV from LV pressure at 
maximum decrement of LV pressure (dP/dtmin) to the level of LV end-diastolic pressure 
(LVEDP), and was first described by Weiss et al. in 1976 (Weiss et al., 1976), and later 
modified by Raff & Glantz (Raff & Glantz, 1981). Similarly to systolic LV parameters, 
however, routinely implementing invasive measurements to evaluate τ is not justifiable 
in healthy people. Therefore, alternative methods such as estimation of blood flow 
velocity through the mitral valve utilizing pulsed Doppler echocardiography are widely 
used to assess LV diastolic function (Nagueh et al., 2009; Rakowski et al., 1996), with 
the limitation that this method measures both active relaxation and myocardial stiffness, 
therefore incorporating passive components of diastolic function. Trans-mitral flow 
velocity comprises two components; peak early (E) and peak atrial (A) filling velocities. 
In the normal heart, most diastolic filling occurs during the early filling phase, so that E 
is characteristically greater than A, and the ratio E/A is usually >1.0 (Rakowski et al., 




2003; Schmidt-Trucksass et al., 2001; Sharma et al., 2002). In some studies, however, 
the A wave was unusually lower than the E wave that can probably be ascribed to the 
lower heart rate, which prolongs the diastolic filling period and reduces the atrial 
component (Fagard et al., 1987). To conclude, studies estimating LV diastolic function 
are consistent that diastolic function is not compromised in athletes despite the presence 
of cardiac hypertrophy. 
2.1.3. Molecular pathways underlying physiological myocardial hypertrophy 
Several pathways have been implicated in the background of physiological myocardial 
hypertrophy, the most important of which being hormones such as insulin, insulin-like 
growth factor-1 or thyroid hormone, and also signal transduction activated by 
mechanical forces. These factors induce physiological myocardial hypertrophy via the 
activation of several signaling pathways converging on phosphoinositide 3-kinase 
(PI3K), Akt, AMP-activated protein kinase or mammalian target of rapamycin (mTOR). 
In the following, I will briefly review the literature on these pathways. 
2.1.3.1. Mechanical forces and signal transduction 
Mechanotransduction enables cardiomyocytes to convert mechanical stimuli into 
biochemical events through the modulation of specific signaling molecules, giving them 
the ability to regulate hypertrophic or atrophic response depending on the extent and 
duration of mechanical stress imposed on them. Molecular pathways implicated in 
mechanotransduction and their significance in cardiac hypertrophy and failure has been 
extensively reviewed recently by Lyon and colleagues (Lyon et al., 2015). Key loci 
within cardiomyocytes in this regard are the sarcomere, the intercalated discs and the 
sarcolemma, which, through a plethora of proteins, are all interconnected, functioning 
as a complex sensor of mechanical stimuli. At the sarcomere, titin and attached proteins 
(such as muscle LIM protein [MLP], titin-Cap [TCAP] or calsarcin-1) serve mainly as a 
stretch sensor and stress response signalosome (Frey et al., 2004a; Gautel, 2011; Knoll 
et al., 2002; Miller et al., 2003). In the intercalated discs, N-cadherin was shown to 
mediate an adaptive response of the cardiomyocyte cytoskeleton to changes in 
mechanical stimuli (Chopra et al., 2011; Kostetskii et al., 2005). Besides the 
intercalated discs at the ends of cardiac myocytes, sarcolemma-associated proteins and 
complexes along the lateral surfaces of elongated myocytes (such as integrins) have 




extracellular matrix (ECM) and the contractile apparatus, costameric structures also 
facilitate the maintenance of mechanical integrity of the sarcolemma (Manso et al., 
2013; Sharp et al., 1997). Furthermore, there is evidence that cardiomyocyte stress 
sensing might be dependent on the direction of the mechanical stimulus (Gopalan et al., 
2003; Simpson et al., 1999), which may be related to different modes of hypertrophic 
growth (Kerckhoffs et al., 2012). 
2.1.3.2. Thyroid hormone-related signaling 
Thyroid hormones have significant biological effect mainly during postnatal growth 
(Stubbe et al., 1978), which effect is partially mediated by the activation of 
PI3K/Akt/mTOR signaling (Kinugawa et al., 2005) (Figure 3.). Whether this hormone 
promotes physiological cardiac hypertrophy in adults, however, is still controversial, but 
studies indicate that thyroid hormone effect convert pathological to physiological 
cardiac hypertrophy (Pantos et al., 2011; Pantos et al., 2007; van Rooij et al., 2007). 
2.1.3.3. Insulin and insulin-like growth factor-1 signaling 
Insulin and insulin-like growth factor-1 (IGF-1) signaling are the most well-known 
pathways in the development of physiological hypertrophy (Figure 3.). Their pathways 
converge on Akt (also known as protein kinase B), which is the main mediator of their 
downstream effects in cardiac myocytes (Catalucci et al., 2009a; Catalucci et al., 2009b; 
Kemi et al., 2008; Kim et al., 2003), although IGF-1 has another canonical pathway 
through extracellular-signal-regulated kinase (ERK), and a non-canonical pathway 
through Gi/phospholipase C (PLC)/inositol-1,4,5-triphosphate (IP3)/Ca2+ signaling 
(Troncoso et al., 2014). Both insulin and IGF-1 are critically important in the pre- and 
postnatal growth of the heart, and both are involved in regulating cell proliferation, 
growth, differentiation, metabolism, and survival (Saltiel & Kahn, 2001; Takeda et al., 
2010; Tatar et al., 2003; Ungvari & Csiszar, 2012; Vinciguerra et al., 2009; Vinciguerra 
et al., 2012). Genetic deletion of IGF-1 leads to a significant decrease in body weight 
during development and usually results in embryonic lethality or death from respiratory 
failure shortly after birth (Liu et al., 1993; Powell-Braxton et al., 1993; Shimizu & 
Minamino, 2016). Similarly, cardio-specific deletion of insulin receptor (IR) results in a 
significant reduction of cardiomyocyte size and heart weight, with persisting fetal gene 
expression profile, mitochondrial dysfunction and reduced cardiac function (Belke et 




the role of IGF-1 and IR mediated signaling in regulating the hypertrophic response 
induced by exercise in an elegant series of experiments. Deletion of the receptors of 
Figure 3. Major molecular factors governing the development of physiological 
hypertrophy 
Physiological hypertrophic growth is induced mainly by growth factors such as insulin, 
IGF-1, or thyroid hormone, and also by periodical mechanical stress occurring during 
strenuous exercise either through pressure- or volume overload. The effects of hormonal 
factors are mediated mostly via the PI3K/Akt/mTOR signaling pathway, while mechanical 
stress exerts its effects through the sarcolemma, intercalated discs and sarcomeres (Lyon et 
al., 2015). 
Akt – protein kinase B; IGF-1 – insulin-like growth factor-1; IGF1-R – IGF-1-receptor; 
mTOR – mammalian target of rapamycin, N-CAD – N-cadherin; PI3K – phosphoinositide-3-




insulin or IGF-1 in cardiomyocytes is associated with reduced or normal baseline 
cardiac growth, respectively, while the hypertrophic response to exercise is normal in 
both cases. When homozygous deletion of either IR or IGF-1 receptor (IGF-1R) is 
aggravated with the deletion of one of the alleles of the other receptor, exercise-induced 
cardiac hypertrophy becomes attenuated as well. The phenotypic changes in exercise-
induced hypertrophy in Igf1r+/−-Ir−/− mice were found to be more severe, which suggests 
that insulin is more closely involved in physiological hypertrophy related to exercise 
than IGF-1 (Ikeda et al., 2009). Nevertheless, cardiac level of IGF-1 was shown to be 
higher in athletes than in sedentary controls, and exercise increased the serum level of 
IGF-1 (Neri Serneri et al., 2001; Poehlman et al., 1994), suggesting a significant role of 
IGF-1 in the development of physiological hypertrophy in humans. 
Akt is the best characterized downstream effector of both insulin and IGF-1 mediated 
signaling, and was shown to promote cardiac hypertrophy via modulation of a variety of 
signaling pathways. Akt was shown to improve Ca2+-handling, enhance cardiac 
contractility and promote physiological cardiac hypertrophy by activating or 
suppressing numerous transcription factors (Figure 3.) (Catalucci et al., 2009a; 
Catalucci et al., 2009b; Condorelli et al., 2002; Matsui et al., 2002; McMullen et al., 
2003; Pallafacchina et al., 2002; Shioi et al., 2000; Shioi et al., 2002; Yamashita et al., 
2001). Taken together, interrelated pathways of insulin and IGF-1 signaling in 
physiological hypertrophy, although both are known to contribute to the phenotypic 




2.2. Pathological myocardial hypertrophy 
2.2.1. Main structural changes in pathological compared with physiological 
myocardial hypertrophy 
While physiological stimuli, such as growth, pregnancy or exercise induce cardiac 
hypertrophy that is associated with maintained structure and function, various 
pathological conditions such as hypertension, myocardial infarction, diabetes mellitus, 
valvular heart disease or cardiomyopathies evoke hypertrophic growth that significantly 
alters the composition of the myocardium. This hypertrophic response of the heart to 
different stressors has been believed to be, at least initially, adaptive and to have a 
compensatory function by diminishing wall stress and thus decreasing myocardial 
oxygen consumption according to the law of Laplace (Grossman et al., 1975; Hood et 
al., 1968; Sandler & Dodge, 1963). It was shown later, however, that the presence of 
LVH developed in response to pathological stimuli, is associated with a significant 
increase in the risk of heart failure and malignant ventricular arrhythmias (Koren et al., 
1991; Levy et al., 1990). 
Similarly to physiological myocardial hypertrophy, two main phenotypes of 
pathological myocardial hypertrophy can be distinguished: (1) concentric hypertrophy 
due to pressure overload originating most commonly from hypertension or stenotic 
valvular disease, which is characterized by parallel addition of sarcomeres and lateral 
growth of individual cardiomyocytes; and (2) eccentric hypertrophy due to volume 
overload (valvular regurgitation or arteriovenous fistulas) or prior infarction, 
characterized by addition of sarcomeres in series and longitudinal cell growth (Dorn et 
al., 2003; Frey et al., 2004b). Furthermore, pathological LVH is usually associated with 
an increased rate of cardiomyocyte death and fibrotic remodeling that promote systolic 
and diastolic dysfunction, rendering it maladaptive in the long term (Berk et al., 2007; 
Spinale, 2007). The combination of LVH with increased levels of biomarkers of 
subclinical myocardial injury (high-sensitivity cardiac troponin T, N-terminal pro–B-
type natriuretic peptide [NT-proBNP]) identifies patients at highest risk for developing 
symptomatic HF, especially HFrEF (Heinzel et al., 2015; Messerli et al., 2017; Seliger 
et al., 2015). In the following, I will summarize the consequences of longstanding 




Hypertension is a major public health problem associated with a significant and rapidly 
increasing mortality worldwide (Figure 1.). The bulk of patients who develop HFpEF 
suffer from persistent hypertension (Steinberg et al., 2012). It is well known that 
hypertensive heart disease (HHD) is initially characterized by compensated LVH, but 
there is considerable inter-individual variability in the increase of LV mass and 
geometry (Drazner, 2011). LV mass can increase from either wall thickening or 
chamber dilation in hypertensive patients; the ratio of LV wall thickness to diastolic 
diameter (relative wall thickness, RWT) classifies LVH as concentric (RWT is 
increased) or eccentric (RWT is not increased), as discussed above (Ganau et al., 1992). 
A third pattern, termed concentric remodeling, occurs when RWT, but not LV mass, is 
increased. Interestingly, contrary to the classical view of concentric hypertrophy slowly 
progressing into eccentric hypertrophy and then to decompensation during the course of 
the disease, hypertensive patients can have any of these patterns of LV geometry as an 
initial hypertrophic response (Ganau et al., 1992; Sehgal & Drazner, 2007). What 
decides whether a patient develops one pattern or another in response to hypertension 
seems likely to be defined by a multitude of variables, including the extent of 
hypertension itself (Fagard et al., 1997; Ross, 1997), ethnicity (Drazner et al., 2005; 
Kizer et al., 2004), sex (Krumholz et al., 1993), age (Chahal et al., 2010; Cheng et al., 
2009), neurohumoral activation (Alderman et al., 2004; Brunner et al., 1972; Davila et 
al., 2008; du Cailar et al., 2000; Muscholl et al., 1998; Nakahara et al., 2007; Olsen et 
al., 2002; Velagaleti et al., 2008), troponin I variants and thus altered Ca2+ sensitivity of 
the contractile apparatus in cardiomyocytes (Davis et al., 2016) and the presence of 
comorbidities such as diabetes or obesity (Avelar et al., 2007; de Simone et al., 1994; 
Gottdiener et al., 1994; Markus et al., 2011; Palmieri et al., 2001; Zabalgoitia et al., 
2001). How these factors combine to generate the final phenotype, however, is yet to be 
discovered. On the molecular level, LVH in response to pathological stimuli such as 
hypertension is characterized by increased myocardial fibrosis (Villari et al., 1995), 
injury or loss of cardiomyocytes (Sano et al., 2007; Shimizu et al., 2010) and coronary 
microvascular rarefaction (Mohammed et al., 2015; Paulus & Tschope, 2013), all of 
which are ultimately contributing to the transition of LVH to HF. Lastly, there is 
evidence that excessive LVH in response to pressure overload might not be necessary to 




which suggests that inhibition of the development of concentric LVH might be a 
potential therapeutic target in pressure overload, such as hypertension (Drazner, 2011; 
Frey et al., 2004b). 
2.2.2. Myocardial dysfunction associated with pathological myocardial 
hypertrophy 
Unlike physiological myocardial hypertrophy that is associated with normal cardiac 
performance, sustained pathological LVH results in both diastolic and systolic 
functional deterioration eventually progressing to HF. This transformation, however, 
might not present itself for extended periods of time, which is termed the compensated 
phase of pathological LVH. During this period, cardiac performance is normal or only 
mildly decreased in spite of the pathological structural alterations already existing in the 
myocardium. Despite the long-known maladaptive nature of pathological myocardial 
hypertrophy, the mechanisms that determine how longstanding hypertrophy ultimately 
progresses to overt heart failure are still poorly understood. Again, as a detailed review 
of the diverse functional consequences of different types of pathological stimuli exceeds 
the limitations of this dissertation, I will focus on the functional deterioration associated 
with longstanding hypertension. 
The causality between maladaptive concentric LVH and diastolic dysfunction was 
established more than 30 years ago (Lorell et al., 1990). In HFpEF patients, LVH is the 
most frequent cardiac structural abnormality, and it is correlated with hospitalization for 
heart failure, cardiovascular death, and aborted cardiac arrest (Hawkins et al., 2007; 
Shah et al., 2014), although the exact mechanisms linking pathological LVH to diastolic 
dysfunction have not been elucidated completely. Nevertheless, HFpEF patients were 
shown to have more pronounced concentric hypertrophy than patients with HHD but 
without HFpEF (Melenovsky et al., 2007). Furthermore, pathological LVH is associated 
with an attenuated increase or even decrease in EF during exercise and reduced exercise 
capacity, this reduction being worst in patients with a concentric type of LVH (Lam et 
al., 2010; Meyer et al., 2015; Schnell et al., 2013). There is evidence that this failure to 
increase EF in response to exercise is not related to an inability to increase LV end-
diastolic volume (LVEDV), therefore to a restriction in LV filling, but rather to a failure 
in the Frank-Starling mechanism in patients with HFpEF (Abudiab et al., 2013; 




role in the diastolic dysfunction related to pathological LVH, as τ in HFpEF patients 
was shown not to decrease during exercise as it normally would in healthy subjects, but 
even become prolonged (Borlaug et al., 2011). 
Many studies have shown that patients with HFpEF display impairments in regional 
deformation detected by tissue Doppler and strain-based imaging techniques, resulting 
in subtle but significant abnormalities in chamber and myocardial contractility, despite 
the overall preservation of EF (Borlaug et al., 2009; Shah & Solomon, 2012; Tan et al., 
2009; Wang et al., 2008). Even this subtle impairment of contractility at rest may 
indicate marked limitations in reserve, which is markedly impaired in HFpEF patients 
compared with age-matched healthy and hypertensive controls (Borlaug et al., 2010). 
Systolic dysfunction affects diastolic function as well, as the ability to contract more 
enhances the recoil and suction forces during early diastole (Opdahl et al., 2009), which 
have also been shown to be impaired in HFpEF (Ohara et al., 2012). 
Animal models are crucially important tools in the discovery of the driving forces 
behind human pathologies. As such, many small and large animal models have been 
developed to model the various clinical conditions resulting in the cardiac phenotype 
discussed above as closely as possible. The most commonly modeled diseases of 
pressure overload of the LV are aortic stenosis via thoracic aortic constriction (Huss et 
al., 2007; Tagawa et al., 1998) and hypertension via renovascular constriction 
(Cangiano et al., 1979; Goldblatt et al., 1934), compression of renal parenchyma 
(Grollman, 1955; Hart et al., 2001), reduction of renal mass (Anderson et al., 1985; Li 
et al., 2009), increased salt intake (Coleman et al., 1975), genetic modifications 
(Molkentin et al., 1998; Okamoto & Aoki, 1963; Pfeffer et al., 1982; Rapp & Dene, 
1985), endocrine stimulation (Bois & Selye, 1957; Krege et al., 1995) and aortic 
banding (Silver et al., 1990; Thiedemann et al., 1983). 
2.2.3. Molecular pathways implicated in pathological myocardial hypertrophy 
During pathological conditions, increased mechanical stress imposed on 
cardiomyocytes is accompanied by modulating factors that eventually shepherd actuated 
hypertrophic signaling pathways in the direction of generating pathological myocardial 
hypertrophy. Regarding the immense complexity of hypertrophic signaling, elucidation 
of the exact mechanism how activated pathways combine to create pathologic LVH is 




  Figure 4. Key molecular pathways implicated in the development of pathological 
myocardial hypertrophy 
Neurohumoral and growth factors together with the increased mechanical stress imposed on 
cardiomyocytes and other cellular components of the myocardium trigger multiple signaling 
pathways that bring about the characteristic phenotypical changes associated with 
pathological left ventricular hypertrophy. The two most important signaling cascades 
involved are Ca2+-related and mitogen activated protein kinase signaling, members of which 
can potently induce gene expression changes generating all major hallmarks of pathological 
myocardial hypertrophy: fibrosis, apoptosis/necrosis and cardiomyocyte hypertrophy. 
CalN – calcineurin; CaMKII – Ca2+/calmodulin dependent kinase II; ERK1/2 – extracellular 
signal-regulated kinase 1/2; GPCR – G protein coupled receptor; IP3 – inositol-1,4,5-
triphosphate; IR – insulin receptor; JNK – c-Jun N-terminal kinase; LTCC – L-type Ca2+ 
channel; MAP3K – MAP2K kinase; MAP2K – mitogen activated protein kinase kinase; PLC 
– phospholipase C; ROS – reactive oxygen species; RTK – receptor tyrosine kinase; TRPC – 




“reactivation of the fetal gene program”, which covers re-expression of a wide array of 
molecular markers that are characteristic to the fetal period of ontogeny. Among others, 
such marker is the isotype-switch of myosin heavy chains (MHCs), significant 
overexpression of atrial natriuretic peptide (ANP), or the increased expression of 
endothelial nitric oxide synthase (NOS3). This altered gene expression profile is the 
driving force in the background of pathological LVH, and in the following section, I 
will shortly summarize the most important pathways initiating it. 
2.2.3.1. Hypertrophy-inducing signals converging on Ca2+-dependent pathways 
Neurohumoral mediators such as catecholamines, angiotensin II or endothelin-1 have all 
been implicated in the development of pathological LVH and in the long term, HF. β-
blockers and angiotensin converting enzyme inhibitors (ACEi) were shown to reduce 
the mortality of HF patients, hence becoming first line pharmacotherapeutic agents in 
HF (AIRE Study Investigators, 1993; Packer et al., 2001; Poole-Wilson et al., 2003). 
These mediators bind to G protein-coupled receptors (GPCRs) that comprise seven 
transmembrane domains. The Gα proteins involved can either be Gαs, Gαi, Gαq or 
Gα12/13, Gαq being the most important for the mediators listed above. Gαq signaling 
activates PLC, which catalyzes the synthesis of IP3, thereby inducing intracellular Ca2+ 
release and thus an increase in [Ca2+]i. The excess Ca2+ can also originate from the 
extracellular space, e.g. through transient receptor potential cation (TRPC) channels. 
TRPCs regulate Ca2+ and Na+ movement in specific microdomains, and were shown to 
be upregulated in pathological myocardial hypertrophy and heart failure (Kuwahara et 
al., 2006; Wu et al., 2010). Regardless of its origin, Ca2+ modulates the activity of 
various Ca2+-dependent signaling pathways, the two most important of which within 
cardiomyocytes being calcineurin/nuclear factor of activated T cells (NFAT) signaling 
and Ca2+/calmodulin-dependent kinase II (CaMKII) signaling. Either of these pathways 
is sufficient to induce pathological LVH alone (Hoch et al., 1999; Kirchhefer et al., 
1999; Molkentin et al., 1998), but interplay between them is highly likely in various 
pathological conditions [Figure 4., (Zarain-Herzberg et al., 2011)]. 
Calcineurin is a Ca2+-activated serine/threonine protein phosphatase that induces 
translocation of NFAT into the nucleus by dephosphorylating it in the cytoplasm, thus 
increasing the expression of genes involved in pathological LVH (Figure 4.). Although 




normal postnatal cardiac growth (Schaeffer et al., 2009), calcineurin/NFAT signaling 
does not seem to be involved in physiological hypertrophy (Wilkins et al., 2004). 
The serine/threonine kinase CaMKII has been known to be involved in heart failure 
based on animal models and clinical data (Ai et al., 2005; Kirchhefer et al., 1999), and 
more recently was implicated in the progression of pressure overload-induced 
pathologic LVH to HF (Ling et al., 2009). 
Forced expression or activation of CaMKII mediates cardiac hypertrophy that is 
phenotypically similar to that of induced by norepinephrine, phenylephrine, or 
endothelin-1, while inhibition of its function prevents pathological LVH and improves 
HF [Figure 4., (Bossuyt et al., 2008; Hoch et al., 1999; Zhu et al., 2000)]. Furthermore, 
class II histone deacetylase (HDAC) phosphorylation by CaMKII was shown to induce 
hypertrophic growth via myocyte enhancer factor-2 (MEF-2) dependent gene 
expression upregulation (Backs et al., 2006; Passier et al., 2000). 
2.2.3.2. Mitogen activated protein kinase (MAPK) pathways in pathological 
hypertrophy 
MAPKs are highly conserved kinases among eukaryotes that are implicated in a wide 
array of cellular processes. In the cardiovascular system, these include cell proliferation, 
cell growth, fibrotic remodeling and cellular response to different stressors. MAPK 
activation involves a three-tiered, phosphorylation based amplification system, during 
which signals originating from GPCRs, receptor tyrosine kinases, ion channels or 
oxidative and other types of stress, including pressure overload, activate the three main 
branches of MAPK signaling: ERK1/2, p38 MAPKs and c-Jun N-terminal kinases 
(JNKs, Figure 4.). All three branches play a role in the development of pathological 
hypertrophy and HF (Gutkind & Offermanns, 2009; Haq et al., 2001; Toischer et al., 
2010), albeit reports so far on these roles are contradictory (Javadov et al., 2014). 
ERK1/2 is implicated in promoting cardiac hypertrophy in response to activation of 
GPCRs by catecholamines, angiotensin II or endothelin-1 and also to increased 
oxidative stress (Figure 4.). Although pro-hypertrophic, ERK1/2 and its downstream 
signaling does not seem to be essential in cardiac hypertrophy, since the deletion of its 
gene (ERK1–/– and ERK2+/–) did not prevent development of LVH (Purcell et al., 2007). 
It does, however, seem to play a role in determining the phenotype (i.e., eccentric or 




Potential downstream targets of ERK1/2-mediated hypertrophy include members of 
Ca2+ homeostasis and activation of the transcription factor GATA4 [Figure 4., (Zheng et 
al., 2004)]. Furthermore, activation of ERK1/2 was shown to play a role in resistance to 
apoptosis (Yamaguchi et al., 2004). 
The role of p38 in the development of pathological hypertrophy is still controversial. 
Although it was shown to promote LVH in some studies (Liang & Molkentin, 2003), 
others concluded that even dramatic down-regulation of the kinase left cardiac 
hypertrophic growth unaffected (Nishida et al., 2004). This discrepancy in the results 
published might be related to methodological differences, such as the use of different 
cell types, animal models, inhibitors or agonists, and also the temporal design of a 
specific study (Javadov et al., 2014). Demonstration of the participation of p38 in 
fibrotic remodeling was more consistent: its activation (Koivisto et al., 2011; Liao et al., 
2001; Wang et al., 1998) or inhibition (Liu et al., 2005; Yin et al., 2008; Zhang et al., 
2003) resulted in enhanced or reduced myocardial fibrosis, respectively (Figure 4.). 
Furthermore, p38 activation is associated with increased apoptosis (Kaiser et al., 2004; 
Ren et al., 2005), thereby promoting the transition of pathologic LVH to overt HF. 
There is, similarly to p38, contradiction in what role JNK plays in the development of 
pathologic LVH. Neonatal cardiomyocytes were shown to respond with hypertrophy to 
targeted activation of JNK signaling (Wang et al., 1998), whereas adult hearts exhibited 
increased hypertrophy, fibrosis and apoptosis when JNK or members of its signaling 
were inhibited (Hilfiker-Kleiner et al., 2005; Liang et al., 2003), suggesting an anti-
hypertrophic role for JNK in adult hearts via interference with calcineurin/NFAT 
signaling (Figure 4.). On the other hand, JNK was shown to induce cardiac dysfunction 
as well via (1) decreasing intercellular communication within the myocardium due to 
the downregulation of connexin-43, and thus loss of gap junctions (Petrich et al., 2002), 
and (2) the activation of matrix metalloproteinase-2 resulting in detrimental cardiac 
remodeling (Krishnamurthy et al., 2007). 
An endogenous negative regulator of MAPK cascades is MAPK phosphatase 1 (MKP-
1), constitutive expression of which in the heart downregulates all three major pathways 
discussed above, and also prevents induction of hypertrophy by catecholamines or 
aortic banding (Bueno et al., 2001). MKP-1 and MKP-4 were shown to have a 




p38MAPK with no change of JNK or ERK1/2 levels, and have a low survival rate 
associated with systolic dysfunction and cardiac dilatation (Auger-Messier et al., 2013). 
2.2.3.3. Excessive activation of insulin signaling contributes to pathological 
myocardial hypertrophy 
Although insulin/IR/Akt signaling is widely accepted to promote physiological 
myocardial hypertrophy, neither animal studies nor large clinical trials have provided 
conclusive evidence whether insulin signaling is cardioprotective in adults. Instead, 
insulin resistance, and thus hyperinsulinemia, has been reported to increase the risk of 
developing heart failure in patients with systolic dysfunction, which observation gains 
epidemiological importance if one considers the high prevalence of this condition 
(Ashrafian et al., 2007; Ingelsson et al., 2005; Witteles et al., 2004). Also, contrary to 
what might be expected, intensive glycemic control with insulin increased 
cardiovascular events in diabetic patients instead of reducing these complications 
(Action to Control Cardiovascular Risk in Diabetes Study Group, 2008). 
Experimental evidence shows that chronic hyperinsulinemia might induce pathological 
hypertrophy via an angiotensin II-dependent manner [Figure 4., (Samuelsson et al., 
2006)], and that excessive insulin signaling exacerbates the transition of hypertrophy to 
overt HF (Shimizu et al., 2010). Furthermore, pressure overload was shown to induce 
adipose tissue inflammation and lipolysis, resulting in insulin resistance (Shimizu et al., 
2012). Suppression of adipose tissue inflammation in the same study decreased insulin 
resistance, therefore, possibly, hyperinsulinemia, and lead to improved systolic function 




2.3. Redox and nitric oxide/cGMP signaling in cardiovascular physiology and 
pathology 
Redox signaling, like many other signaling pathways implicated in cardiovascular 
physiology, is Janus-faced. Whether physiological processes or detrimental effects are 
mediated by reactive oxygen (ROS) and nitrogen species (RNS), depends on the local 
concentration and compartmentation of the reactive species involved, and also on the 
capacity of antioxidant mechanisms present. Oxidative and nitrosative stress, in fact, 
cannot be meaningfully separated, as generation of either ROS or RNS will bring about 
the genesis of the other, hence the term nitro-oxidative stress. 
Previously known as the elusive endothelial-derived relaxing factor [EDRF, (Furchgott 
& Zawadzki, 1980)], the discovery of nitric oxide (NO) and its involvement in many 
physiological processes and virtually all cardiovascular pathologies reestablished our 
thinking concerning cardiovascular health and disease. NO, though often referred to as a 
toxic agent when present in higher concentrations and thus considered a major player in 
nitrosative stress, is not particularly reactive. There is, however, one reactive species 
that seems to stand out from the rest, especially in terms of biological importance: 
peroxynitrite, a powerful oxidant that is formed in a spontaneous reaction between NO 
and superoxide (Pacher et al., 2007). 
The cardioprotective effects of NO, mediated intracellularly via cGMP signaling, are 
severely reduced in disease states, including hypertension, associated with increased 
nitro-oxidative stress. Therefore, novel pharmacological approaches specifically 
targeting the upregulation of this physiologically important pathway are increasingly 
investigated. In the following section, I will briefly review the most important aspects of 
redox- and NO signaling in cardiovascular homeostasis and pathology, and also give a 
short introduction into the concept of sGC activation as a novel pharmacological 
interventional option. 
2.3.1. The role of redox signaling in cardiac (patho)physiology 
2.3.1.1. Forms, sources, targets and elimination of reactive oxygen species in the heart 
ROS are powerful oxidants that contain at least one oxygen atom with an unpaired 
electron. The most important ROS in vivo are superoxide anion (O2
-) and hydrogen 




singlet oxygen also play a significant role. ROS can either be generated by nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases (Noxs) that are specialized enzymes 
having no known biological role other than forming ROS, or can originate from the 
functioning of the mitochondrial electron transport chain, oxidases involved in 
metabolism (e.g. xanthine oxidase and monoamine oxidases) and uncoupled NO 
synthases as by-products [Figures 5. and 6., (Burgoyne et al., 2012)]. The 
compartmentation and local concentration of ROS produced have a significant role in 
their effect, as these define the targets they can reach; in cardiomyocytes, these redox 
sensitive targets include CaMKII (Erickson et al., 2008), cAMP-dependent protein 
kinase (PKA, Brennan et al., 2006), cGMP-dependent protein kinase (PKG, Burgoyne 
et al., 2007), MAPKs (Valko et al., 2007) and members of Ca2+ homeostasis such as 
ryanodine receptor 2 (RyR2) and sarcoplasmic and endoplasmic reticulum Ca2+-ATPase 
2a (SERCA2a, Zima & Blatter, 2006). An efficient endogenous antioxidant system 
comprising enzymatic and non-enzymatic components exists to scavenge and thus limit 
the effects of ROS both spatially and temporally. Superoxide dismutase (SOD) 
catalyzes the conversion of O2
- to H2O2, which is then further converted by catalase 
(Cat) and glutathione peroxidase to water and molecular oxygen. Furthermore, non-
enzymatic defense is represented by ascorbic acid (vitamin C), α-tocopherol (vitamin 
E), glutathione, carotenoids, flavonoids and other antioxidants such as thioredoxin 
(Burgoyne et al., 2012; Valko et al., 2007). 
2.3.1.2. Oxidative stress and its role in pathological myocardial hypertrophy 
Reviewing all the known ROS-related mechanisms in the background of cardiovascular 
pathologies would significantly exceed the possibilities of this dissertation; therefore, I 
will focus on pathological myocardial hypertrophy and relevant mechanisms including 
alterations in Ca2+ handling and induction of apoptosis/necrosis. 
Oxidative modification of CaMKII (Wagner et al., 2011), RyR2 (Terentyev et al., 2008) 
and SERCA2a (Lancel et al., 2010) all contribute to the imbalance of cellular Ca2+ 
homeostasis in pathological LVH (Figure 5.). Diastolic Ca2+ leakage through oxidized 
RyR2 and SERCA2a results in increased [Ca2+]i and thus impaired relaxation, 
contractile dysfunction and increased probability of arrhythmias. Oxidation-enhanced 





Mitochondria play a central role in orchestrating apoptotic/necrotic cell death in 
response to ROS and Ca2+ overload (Sack et al., 2017). Mitochondrial permeability 
transition pore opening or translocation of pro-apoptotic proteins Bax/Bad to the 
mitochondria are both central processes in the intrinsic pathway of apoptotic cell death 
Figure 5. Major redox-sensitive targets with a significant role in the development 
of pathological myocardial hypertrophy 
Reactive oxygen species are capable of activating key players of pathological hypertrophic 
growth independently of their original activators. ROS, therefore, further enhance the over-
activation of hypertrophic signaling, resulting in an aggravated hypertrophic phenotype. 
CaMKII – Ca2+/calmodulin dependent kinase II; MAP2K – mitogen activated kinase kinase; 
MAP3K – MAP2K kinase; NOX2 – nicotinamide adenine dinucleotide phosphate oxidase 2; 
ROS – reactive oxygen species; RyR2 – ryanodine receptor 2; SERCA2 – sarcoplasmic and 




facilitated by ROS (Donath et al., 2006). Excessive GPCR activation also leads to ROS 
production and activation of JNK and p38 MAPK, leading to activation of apoptotic 
pathways (Yamaguchi et al., 2003). 
As discussed above, both Ca2+-dependent and MAPK signaling involved in cardiac 
hypertrophy might also be activated by ROS; in fact, due to the interdependence of the 
effects of vasoactive mediators and ROS, they cannot meaningfully be separated in 
pressure overload-induced LVH. Nox2 is of central importance in generating the 
reactive species activating/interfering with hypertrophic signaling actuated by other 
factors [Figure 5., (Bendall et al., 2002; Grieve et al., 2006)], but activation of Nox2 is 
certainly not obligatory for the development of pressure overload-induced LVH (Maytin 
et al., 2004; Touyz et al., 2005). Furthermore, mechanical stretch has also been 
associated with ROS-mediated induction of hypertrophy, also via the activation of Nox2 
(Pimentel et al., 2001). 
2.3.2. Nitric oxide and cGMP signaling in cardiovascular health and disease 
NO, despite its simple structure comprising only two atoms, is among the most 
important intercellular messengers in all vertebrates, playing a significant role in the 
modulation of thrombosis, neural activity and cardiovascular homeostasis (Pacher et al., 
2007). NO mediates its effects mainly through increasing the generation of cGMP, but 
also has cGMP-independent effects via protein nitrosylation (Lima et al., 2010), here 
not discussed in more detail. Certain disease conditions, especially those associated with 
oxidative stress result in the dysfunction of this important pathway, which will be 
reviewed briefly in this section. 
2.3.2.1. cGMP generation and degradation  
NO in the cardiovascular system is predominantly produced by NOS3 located in the 
endothelium, but cardiac myocytes are also capable of producing it – mainly for tightly 
localized regulatory purposes – by neuronal NOS (NOS1). NOS3-derived NO then 
diffuses to its target cells, including cardiomyocytes, to activate sGC. The enzyme binds 
NO with its heme moiety (Derbyshire & Marletta, 2009), resulting in an up to 800-fold 
increase in its activity and a production of cGMP from GTP in a similar magnitude. 
sGC, however, is not the only source of cGMP within the cell. Membrane-bound 
enzymes, particulate GCs (pGCs) also produce it in response to natriuretic peptides 




cGMP generated in response to these peptides differ from that of derived from sGC, 
therefore cardiomyocytes exhibit distinct responses as well (Castro et al., 2006; 
Fischmeister et al., 2006); ANP has anti-hypertrophic properties (Patel et al., 2005), 
while BNP mediates anti-fibrotic effects (Tamura et al., 2000). CNP does not play a 
significant role in the cGMP-generation of cardiomyocytes (Yasoda et al., 2004). 
cGMP is removed from the cell by either enzymatic degradation or extrusion via multi 
drug resistance proteins. Enzymatic degradation is responsible for the bulk of cGMP 
elimination, and is catalyzed by cyclic nucleotide-specific phosphodiesterases (PDEs), 
Figure 6. NO-cGMP signaling in health and disease 
Physiological signaling through the NO/cGMP/PKG pathway deteriorates at multiple levels 
under pathological conditions. Oxidative stress decreases the generation, amount and 
sensing of nitric oxide by target cells, therefore disrupting cGMP generation and signaling 
within these cells as well. There have been various attempts at restoring cGMP signaling in 
cardiovascular pathologies, these are marked with yellow color. The novel sGC stimulators 
require reduced, functional sGC to mediate their effects, while sGC activators are capable 
of inducing cGMP production of dysfunctional sGC in absence of its heme prosthetic group 
(Evgenov et al., 2006) 
BH4/2 – reduced/oxidized tetrahydrobiopterin; cGMP – cyclic GMP; GMP – guanosine 
monophosphate; MAO – monoamine oxidase; NO – nitric oxide; NOS3 – endothelial NO 
synthase; NOX – nicotinamide adenine dinucleotide phosphate oxidase; ONOO- – 
peroxynitrite; PDE5/9 – phosphodiesterase 5/9; PKG – cGMP dependent kinase; ROS; 




which are members of a superfamily comprising eleven smaller families (PDE1-11). 
PDEs have distinct specificities for cAMP and cGMP, among which PDE5 and PDE9 
are significant in the cardiovascular system regarding the hydrolysis of cGMP (Lee et 
al., 2015; Takimoto et al., 2005a). 
2.3.2.2. cGMP-dependent effects of nitric oxide signaling 
cGMP mediates its effects through a number of mechanisms. Predominantly it activates 
PKGs and thus regulates phosphorylation state of various protein targets, but it can also 
modulate the activity of distinct PDEs and cAMP-dependent protein kinases either 
directly or indirectly (termed as cAMP-cGMP crosstalk). Most cells contain at least one 
of three PKGs: PKGIα, PKGIβ, or PKGII that are targeted by their distinct amino 
termini to different substrates (Hofmann et al., 2009). Cardiomyocytes express PKGIα, 
which resides within the cell in a soluble form. PKGIα has been established to be a 
powerful brake on the cellular stress response signaling [Figure 6., (Hofmann, 2018; 
Rainer & Kass, 2016)]: it can suppress selective GPCR agonism through regulator of G 
protein signaling subtypes (Takimoto et al., 2009), phosphorylate titin and troponin I 
(Kruger et al., 2009; Lee et al., 2010), increase the activity of late rectifier K+-channels 
(Bai et al., 2005) and antagonize members of the TRPC channel family (Koitabashi et 
al., 2010; Wu et al., 2010). More recently it was discovered that PKG might also 
modulate mechanosensing (Seo et al., 2014) and protein quality control (Ranek et al., 
2013). In addition, as described above, oxidation of the PKG1α isoform in 
cardiomyocytes impairs its brake-like function; therefore oxidative stress adversely 
impacts stress-response signaling (Nakamura et al., 2015). 
2.3.2.3. Oxidative stress results in an imbalance in NO-cGMP signaling 
Oxidative stress impairs NO signaling at multiple levels (Figure 6.). 
Tetrahydrobiopterin, which serves as a prosthetic group in NOS3, becomes oxidized, 
which results in uncoupling of the enzyme. Uncoupled NOS3 cease to produce NO, and 
instead, starts production of O2
-, thereby aggravating oxidative stress [Figure 6., (Stasch 
et al., 2011)]. NO bioavailability is further reduced by its instantaneous conversion to 
peroxynitrite by O2
-. Peroxynitrite is a strong oxidant itself, mediating nitro-oxidative 
stress by nitrating tyrosine residues of various proteins and damaging other targets 
(Pacher et al., 2007). Oxidative stress results in damaged sGC via the oxidation of its 




rendering sGC incapable of generating cGMP (Evgenov et al., 2006). Furthermore, 
cGMP degradation is increased in oxidative stress mainly because of upregulation of 
PDE5 (Das et al., 2015). As a result, cGMP level within cardiomyocytes becomes 
significantly decreased, resulting in the loss of its cardioprotective effects. 
2.3.3. Modulation of sGC activity – a novel pharmacotherapeutic concept 
Long before any knowledge regarding the mechanism of their action, glyceryl trinitrate 
and other organic nitrates, as well as nitro-vasodilators had been in clinical use to treat 
angina pectoris and hypertensive crises for decades (Megson & Miller, 2009). Most of 
these drugs, however, have an important limitation: they lose their efficacy during 
prolonged use, termed as nitrate tolerance (Munzel et al., 2005). Furthermore, NO 
resistance is an important feature of ischemic heart disease and hypertension, and is also 
present in a significant portion of patients with pulmonary hypertension. The discovery 
that cGMP generated by sGC, as discussed above, mediates the cardioprotective effects 
associated with NO, provided rationale for development of new pharmaceuticals acting 
at different steps of the NOS3-NO-sGC-cGMP-PKG axis, potentially downstream of 
NO (Figure 6.). 
sGC stimulation and activation as a highly effective method to increase intracellular 
cGMP-production, have been subject to extensive preclinical and clinical research 
(Boerrigter et al., 2007; Schmidt et al., 2009; Stasch et al., 2015; Stasch & Hobbs, 
2009). sGC stimulators require sGC to be functional (i.e., sGC having an intact, reduced 
heme prosthetic group) to increase cGMP production, and synergize with NO in 
activation of the enzyme [Figure 6., (Evgenov et al., 2006)]. A sGC stimulator, 
riociguat under the trade name Adempas®, has recently been approved by the Food and 
Drug Administration for clinical use in pulmonary hypertension based on data from a 
large, randomized, Phase III clinical trial (Ghofrani et al., 2013). sGC activators, in 
contrast, are capable of activating sGC independently of both NO and heme, therefore 
might be more potent in cardiovascular conditions with oxidative stress where sGC 
activity is severely diminished (Figure 6.). 
Cinaciguat (also known as BAY 58-2667) was the first sGC activator to be developed, 
and remains the most potent such drug to this day. Due to its strong and selective 
binding to heme-free and thus inactive sGC (Figure 7.) prevalent mainly in conditions 




potentially disease-selective mode of action. It has been shown to have beneficial 
effects in various cardiovascular disorders, such as myocardial infarction (Korkmaz et 
al., 2009), ischemia/reperfusion injury (Radovits et al., 2011), endothelial dysfunction 
induced by nitro-oxidative stress (Korkmaz et al., 2013), vascular neointima formation 
(Hirschberg et al., 2013) and diabetic cardiomyopathy (Matyas et al., 2015), as well as 
preservation of the donor organ during heart transplantation (Loganathan et al., 2015). 
Clinical trials in which the drug was used in acute heart failure patients intravenously, 
however, have not been successful so far (Erdmann et al., 2013). Alternative temporal 
and drug delivery designs in other patient populations, such as chronic oral 
administration in HFpEF patients, as well as development of short-acting sGC 
activators (Sawabe et al., 2019), however, might still be feasible, and need further 
investigation. 
  
Figure 7. Structural similarity of heme and cinaciguat 
Heme serves as the nitric oxide sensor in soluble guanylate cyclase. Under pathological 
conditions that are associated with increased oxidative stress, the ferrous ion in the center of 
heme becomes oxidized, and the resulting conformational change leads to the dissociation of 
the prosthetic group from the enzyme. Due to its structural homology, cinaciguat binds into 






Although both physiological and pathological myocardial hypertrophy have been 
extensively studied from molecular viewpoints, functional data regarding the 
differences between these hypertrophic phenotypes is limited in terms of reliability, 
given the non-invasive and thus less accurate modalities used to describe them. 
Therefore, there is a need to provide a deeper insight into the functional alterations 
characterizing these distinct forms of cardiac hypertrophy. Furthermore, the incidence 
of heart failure is continuously rising, largely because of the growing incidence of its 
preceding conditions such as longstanding hypertension. 
Our aims for the experimental investigations discussed in this thesis were as follows: 
(1) Compare the functional characteristics of physiological and pathological 
myocardial hypertrophy utilizing P-V analysis, the current gold standard method for in 
vivo cardiac functional measurements 
(2) Explore the morphological and molecular background of the functional 
differences observed in physiological and pathological myocardial hypertrophy 
(3) Characterize the effect of the sGC activator cinaciguat in pathological 
myocardial hypertrophy from morphological, functional and molecular points of view 




4. Materials and Methods 
All animals received humane care in compliance with the “Principles of Laboratory 
Animal Care”, formulated by the National Society for Medical Research and the Guide 
for the Care and Use of Laboratory Animals, prepared by the Institute of Laboratory 
Animal Resources and published by the National Institutes of Health (NIH Publication 
No. 85-23, Revised 1996). All procedures and handling of the animals during the 
studies were reviewed and approved by the Ethical Committee of Hungary for Animal 
Experimentation.  
Young adult (body weight=200–250 g) male Wistar rats (n=58) (Toxi-Coop, Dunakeszi, 
Hungary) were housed in a room with constant temperature of 22±2°C with a 12h light-
dark cycle, were fed a standard laboratory rat chow ad libitum and had free access to 
water. 
4.1. Experimental protocols, treatment groups 
4.1.1. Differences between physiological and pathological myocardial hypertrophy 
4.1.1.1. Exercise training 
To induce physiological hypertrophy, we used swimming to train our animals, utilizing 
a swimming apparatus designed specifically for rats. A suitable water tank 40 cm in 
depth was divided into 6 lanes with a surface area of approximately 20x25cm to prevent 
rats from reclining on the walls, and filled with tap water (30-32°C) to allow for 
individual training. Based on literature data (Evangelista et al., 2003) and on results of 
preliminary pilot studies of our own, long-term (a total of 12 weeks) exercise training in 
the exercised (Ex; n=12) group consisted of 200 minutes/day of swimming 5 days a 
week, gradually built up in 15-minute blocks every other training session (Figure 8., A). 
Untrained sedentary (Sed; n=11) rats were placed into the water for 5 minutes every 
training day during the training program to control for the possibility of stress resulting 
from exposure to water. 
4.1.1.2. Aortic banding procedure 
After acclimation, pathological myocardial hypertrophy was induced by banding of the 
abdominal aorta (AAB, n=10) between the renal arteries and the superior mesenteric 




anesthesia. In order to achieve a standard degree of stenosis in our aortic banded 
animals, a blunted needle with an outer diameter of 20 Gauge (G, 0.9mm) was placed in 
parallel with the aorta, around which a 2-0 surgical suture was tightened in all cases. 
Then, the needle was removed, leaving a standard 20G stenosis behind. Sham operation 
comprised all steps excluding the banding procedure, which was replaced by a 1 min 
occlusion at the same level of the aorta. After recovering from anesthesia and on the 
Figure 8. Schematic diagram 
of the implemented protocols 
A: Scheme of the protocol to 
investigate differences between 
hypertrophic phenotypes. The 
length of exercise was gradually 
increased until reaching 200 
minutes 5 days a week (top row). 
Sedentary rats swam 5 minutes 
every training day. Aortic banding 
or sham operation (bottom row) 
was followed by 6 weeks of 
observation. 
B: Scheme of the protocol to 
investigate the effect of cinaciguat 
in pathological hypertrophy. 
Following aortic banding or sham 
operation, cinaciguat or placebo 
was administered to the rats via 
oral gavage after the 2nd 
postoperative day. Treatment 




first and second postoperative day, all animals received meloxicam (1.5mg/kg p.o.) for 
postoperative analgesia. At the end of the 6 weeks of observation, all animals were 
subjected to functional measurements, as described below (Figure 8. A). 
4.1.2. Effects of cinaciguat in pathological myocardial hypertrophy 
The AAB procedure or sham operation was executed as described above. 
5 days after the operation, sham and AAB animals were randomized into control or 
treatment groups [ShamCo, n=8; ShamCin, n=8; AABCo, n=10; AABCin, n=9, (Figure 
8. B)]. Treated animals received cinaciguat (10mg/kg p.o.) suspended in 0.5% 
methylcellulose solution via oral gavage, while control rats were given only the vehicle 
every day for 6 weeks. The dosage was adjusted to body weight, which was measured 
three times a week during the whole study period. 
4.2. Echocardiography 
Echocardiographic measurements were performed at the end of the training program 
(Ex and Sed rats) and on the 3rd and 6th week (AAB and Sham animals). The rats were 
anesthetized with pentobarbital sodium (60mg/kg i.p.), and were placed on controlled 
heating pads. Core temperature of the animals, measured via rectal probe, was 
maintained at 37°C. After the anterior chest was shaved, transthoracic echocardiography 
was performed in the supine position by an investigator blinded to the experimental 
groups. Two-dimensional and M-mode echocardiographic images of long- and short-
axis were recorded using a 13-MHz linear transducer (GE 12L-RS, GE Healthcare, 
Waukesha, WI, USA) connected to a commercially available echocardiographic 
imaging unit (Vivid i, GE Healthcare). Digital images were analyzed by an investigator 
in blinded fashion using an image analysis software (EchoPac, GE Healthcare). On two-
dimensional recordings of the short-axis at the mid-papillary muscle level, left 
ventricular anterior wall thickness (AWT), posterior wall thickness (PWT) in diastole 
(index: d) and systole (index: s), and LV end-diastolic (LVEDD) and end-systolic 
(LVESD) diameters were measured. In addition, end-diastolic and end-systolic LV 
areas were planimetered from short- and long-axis two-dimensional recordings. End 
systole was defined as the time point of minimal LV dimensions, and end diastole as the 




cycles. The following parameters were derived from these measurements: FS was 
calculated as [(LVEDD-LVESD)/LVEDD]*100. End-diastolic and end-systolic 
(LVESV) LV volumes were estimated according to a validated geometrical model, the 
biplane ellipsoid model (van de Weijer et al., 2012). Stroke volume (SV) was calculated 
as LVEDV-LVESV. EF was determined as (SV/LVEDV)*100. LV mass (LVM) was 
calculated according to a cubic formula, suggested by Devereux et al. (Devereux et al., 
1986): LV mass = ([(LVEDD+AWTd+PWTd)3-LVEDD3]*1.04)*0.8+0.14. To 
calculate LVM index (LVMi), we normalized the LVM values to the body weight of the 
animal. 
4.3. Hemodynamic Measurements: LV Pressure-Volume (P-V) Analysis 
Rats were anesthetized with pentobarbital sodium (60mg/kg i.p.), tracheotomized, 
intubated and ventilated with a tidal volume and frequency adjusted to body weight, 
using an Inspira Advanced Safety Ventilator (MA1 557058, Harvard Apparatus, 
Holliston, MA, USA). Animals were placed on controlled heating pads, and the core 
temperature, measured via rectal probe, was maintained at 37°C. A polyethylene 
catheter was inserted into the left external jugular vein for fluid administration. A 2-Fr 
micro tip pressure-conductance catheter (SPR-838, Millar Instruments, Houston, TX, 
USA) was inserted into the right carotid artery and advanced into the ascending aorta. 
After stabilization for 5 minutes, arterial blood pressure and heart rate (HR) were 
recorded. Then, the catheter was advanced into the LV under pressure control (Figure 
9.). After stabilization for another 5 minutes, signals were continuously recorded at a 
sampling rate of 1,000 samples/s using a P-V conductance system (MPVS-Ultra, Millar 
Instruments) connected to the PowerLab 16/30 data acquisition system (AD 
Instruments, Colorado Springs, CO, USA), stored, and displayed on a personal 
computer by the LabChart7 Software System (AD Instruments). LV end-systolic 
pressure and volume (LVESP and LVESV), LV end-diastolic pressure and volume 
(LVEDP and LVEDV), the maximum rate of LV pressure increment (dP/dtmax), time 
constant of LV pressure decay (τ, according to the Glantz method), EF and stroke work 
(SW) were computed and calculated using a special P-V analysis program (PVAN, 
Millar Instruments). SV and cardiac output (CO) were calculated and corrected 




addition to the above parameters, P-V loops recorded at different preloads can be used 
to derive other useful indices of systolic function that are less influenced by loading 
conditions and cardiac mass (Oláh et al., 2015). Therefore, LV P-V relations were 
measured during transiently decreasing preload, which was achieved by the 
compression of the inferior vena cava proximal to the diaphragm with a cotton-tipped 
applicator. The slope [end-systolic elastance (Ees)] of the LV end-systolic P-V 
relationship [ESPVR, Figure 10.; according to the parabolic curvilinear model (Kass et 
al., 1989)], preload recruitable SW (PRSW), and the slope of the dP/dtmax-end-diastolic 
volume relationship (dP /dtmax-EDV) were calculated as load-independent indices of LV 
Figure 9. Schematic figure on the principle of operation and localization of the 
pressure-conductance micro tip catheter within the rat heart 
The catheter must be in the axis of the ventricle in order to accurately measure LV pressures 
and volumes. The pressure sensor (blue) continuously measures pressure changes in the LV 
utilizing a piezoresistive semiconductor. Volume is measured using 4 electrodes (gold); the 
electric field generated by the outer electrode pair is attenuated depending on the size of the 
current blood volume (i.e., contraction and relaxation during the cardiac cycle) within the 
LV. This fluctuation in the electric field and the resulting voltage potentials are measured by 
the inner – sensing – pair of electrodes. Since this method measures LV volumes indirectly, 
blood conductance calibration has to be performed in order to convert the measured relative 




contractility. LV compliance was investigated by calculating the slope of end-diastolic 
pressure-volume relationship (EDPVR, Figure 10.). Pressure-volume area (PVA) was 
also calculated utilizing the lines of ESPVR, EDPVR, and the systolic segment of the 
steady state P-V loop (Figure 10.). At the end of each experiment, 100 µl of hypertonic 
saline was injected intravenously to calculate parallel conductance volume from the 
shift of P-V relations. Parallel conductance was calculated by the PVAN software and 
used to correct for the cardiac mass volume. The volume calibration of the conductance 
system was performed using a block with nine, 1 cm deep cylindrical holes, which had 
known diameters (and thus known volume) ranging from 2 to 11 mm. Each hole was 
Figure 10. Representative P-V recording during the inferior vena cava occlusion 
maneuver, and the parameters directly derivable from the acquired loops 
Occlusion of the inferior vena cava results in the left- and downward shift of the P-V loops. 
End-systolic pressure-volume relationship (ESPVR) and end-diastolic pressure-volume 
relationship (EDPVR) are the lines defined by the end-systolic and end-diastolic points, 
respectively. Stroke work (SW, yellow fill) can be calculated as the area enclosed by the 
baseline P-V loop, while pressure-volume area (PVA, marked with red) is bound by the 




filled with fresh heparinized whole rat blood. In this calibration, the linear volume-
conductance regression of the absolute volume in each cylinder versus the raw signal 
acquired by the conductance catheter was used as the volume calibration formula. After 
completion of the hemodynamic measurements all animals were euthanized by 
exsanguination. 
4.4. Measurement of organ weights and tibia length 
After euthanasia, the heart, the lung and the liver of the animals were immediately 
placed into ice-cold saline and wet weight of the organs was measured on a scale. This 
was followed by the sampling of the organs, as described below. To exclude the natural 
variability between the bodyweight of the animals, the right tibia of every rat was also 
prepared and its length measured (Yin et al., 1982). 
4.5. Histology and immunohistochemistry 
Heart samples were placed in 4% buffered paraformaldehyde solution. Transverse 
transmural slices of the ventricles were sectioned (5 µm) and conventionally processed 
for histological examination. Heart sections were stained with hematoxylin and eosin 
(H&E) and Picrosirius red. Light microscopic examination was performed with a Zeiss 
microscope (Axio Observer.Z1, Carl Zeiss, Jena, Germany), and digital images were 
captured using an imaging software (QCapture Pro 6.0, QImaging, Surrey, BC, 
Canada). 
4.5.1. Cardiomyocyte diameter measurement 
The transverse transnuclear widths of randomly selected, longitudinally oriented 
cardiomyocytes were measured on H&E-stained sections by a single investigator after 
calibration of the system. The mean value of 100 LV cardiomyocytes represents each 
sample. 
4.5.2. Assessment of LV collagen content 
The amount of myocardial collagen was determined by measuring the area fraction of 




of five randomly selected visual fields (magnification, 200x) of free LV wall represents 
each sample. 
4.5.3. cGMP immunostaining 
5µm thick sections of formalin-fixed, paraffin-embedded heart samples were 
deparaffinized with xylene, and rehydrated through descending concentrations of 
ethanol. After blocking unspecific binding sites with 5% goat serum for 30 minutes at 
room temperature, immunohistochemical staining for cGMP was performed using the 
avidin-biotin method. An anti-cGMP rabbit monoclonal primary antibody (dilution: 
1:2000, Abcam, Cambridge, UK) was applied for 60 minutes at room temperature. A 
biotinylated secondary anti-rabbit antibody (BioGenex, Fremont, CA, USA) was 
applied for 20 minutes, after which the slides were exposed to streptavidin-conjugated 
alkaline phosphatase (BioGenex). Between each step, all slides were subjected to two 5-
minute rinses with Tris-buffered saline. The DAKO® Fast Red Substrate System (Dako, 
Santa Clara, CA, USA) was used for antigen visualization. Color development was 
stopped by addition of distilled water, which was followed by counterstaining with 
hematoxylin. Negative control staining comprised all steps save the primary antibody. 
Immunohistochemical reactivity was examined with light microscopy at a magnification 
of 400x. Semi-quantitative scoring (scores 0–4; 0: no staining, 1: weak, 2: mild, 3: 
strong, 4: very strong staining) was performed by two people blinded to the groups. 
4.5.4. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay 
Paraffin embedded, 5µm thick heart tissue sections were used to detect DNA strand 
breaks in LV myocardium. TUNEL assay was performed using a commercially 
available kit (DeadEnd™ Colorimetric TUNEL System, Promega, Mannheim, 
Germany) according to the manufacturer’s protocol. Briefly, fragmented DNA of 
apoptotic cells were end-labeled using a modified TUNEL assay. Biotinylated 
nucleotides were incorporated at the 3´-OH DNA ends using a recombinant terminal 
deoxynucleotidyl transferase (rTDT) enzyme. Horseradish peroxidase-labeled 
streptavidin (Streptavidin HRP) was then bound to these biotinylated nucleotides, which 




chromogen, diaminobenzidine (DAB). TUNEL positive cell nuclei were counted by two 
blinded observers in 10 fields of each section at 200x magnification. Data were 
normalized to the mean value of the ShamCo group and were used to perform statistical 
analysis. 
4.6. Biochemical Measurements 
After hemodynamic measurements were completed, blood samples from the inferior 
vena cava were collected in tubes rinsed with ethylenediamine-tetraacetic acid (EDTA). 
The blood samples were centrifuged at 3,000 RPM for 15 min at 4°C, and then 
separated plasma was stored in aliquots at -80°C. Plasma level of cGMP was 
determined using an enzyme immunoassay (EIA) kit as per manufacturer’s protocol 
(Amersham cGMP EIA Biotrak System, GE Healthcare, Little Chalfont, 
Buckinghamshire, UK). 
4.7. Cardiac mRNA Analysis  
LV myocardial tissue samples were snap frozen in liquid nitrogen, and stored at -80°C. 
LV tissue was homogenized in RLT buffer, and RNA was isolated from the ventricular 
samples using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions and quantified by measuring optical 
density at 260nm. RNA purity was ensured by obtaining a 260/280nm optical density 
ratio of >2.0. Reverse transcription reaction (1µg total RNA of each sample) was 
completed using the QuantiTect Reverse Transcription Kit (Qiagen). Quantitative real-
time PCR was performed with the StepOne-Plus Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA) in triplicates of each sample in a volume of 10µl in 
each well containing cDNA (1µl), TaqMan Universal PCR MasterMix (5µl), and a 
TaqMan Gene Expression Assay for the following targets (0.5µl, Table 1.): MHCα, 
MHCβ, NOS3, ANP, B cell lymphoma 2 (Bcl-2), 70kDa heat shock protein (HSP70), 
SERCA2a and Pln, endogenous antioxidants, such as catalase, superoxide dismutase-2  
(SOD-2), and thioredoxin-1 (Trx1); inflammatory markers, such as interleukin-1β (IL-
1β), tumor necrosis factor α (TNFα), and transforming growth factor β  (TGFβ); and 




Table 1. TaqMan® Gene Expression Assays used for qRT-PCR 
Target gene Abbreviation Assay ID 
B-cell CLL/lymphoma 2 Bcl-2 Rn99999125_m1 
catalase Cat Rn00560930_m1 
cytochrome-c CytC Rn00470541_g1 
endothelial nitric oxide synthase NOS3 Rn02132634_s1 
estrogen-related receptor α ERRα Rn00433142_m1 
glyceraldehyde-3-phosphate 
dehydrogenase GAPDH Rn01775763_g1 
heat shock 70kD protein 1A HSP70 Rn04224718_u1 
interleukine-1β IL-1β Rn00580432_m1 
myosin heavy chain α MHCα Rn00568304_m1 
myosin heavy chain β MHCβ Rn00568328_m1 
natriuretic peptide A ANP Rn00561661_m1 
nuclear respiratory factor 1 Nrf1 Rn01455958_m1 
peroxisome proliferator-activated 
receptor γ coactivator-1α PGC1α Rn00580241_m1 
peroxisome proliferator-activated 
receptor α PPARα Rn00566193_m1 
phospholamban Pln Rn01434045_m1 
sarcoplasmic and endoplasmic 
reticulum Ca2+-ATPase isoform 2a SERCA2a Rn00568762_m1 
superoxide dismutase-2 SOD-2 Rn00690587_g1 
thioredoxin-1 Trx1 Rn00587437_m1 
transforming growth factor β TGFβ Rn00572010_m1 




receptor γ coactivator 1α (PGC1α), nuclear respiratory factor 1 (Nrf1), estrogen-related 
receptor α  (ERRα), peroxisome proliferator-activated receptor α (PPAR α), and 
cytochrome c (CytC), all purchased from Applied Biosystems. Gene expression data 
were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; reference 
gene), and expression levels were calculated using the CT comparative method (2-∆CT). 
All results are expressed as values normalized to a positive calibrator, which was a pool 
of cDNAs from all samples of the Sed and Sham, as well as the ShamCo group in the 
respective experiments. 
4.8. Immunoblot analysis 
LV tissue samples were homogenized in radio-immunoprecipitation assay lysis buffer 
(RIPA; 50mM Tris HCl at pH 8.0, 150mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate [SDS]) containing Complete Protease 
Inhibitor Cocktail (Roche, Mannheim, Germany). Protein concentration was determined 
using the Pierce® BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 
Samples were mixed with 2× Laemmli buffer and boiled at 95ºC for 5 min. Equal 
amounts of protein (30 µg) were loaded and separated on commercially available, 
precast 4–12% SDS-PAGE gels (NuPAGE® Novex® Bis-Tris Mini Gel, Invitrogen, 
Carlsbad, CA, USA). Afterwards, proteins were transferred to nitrocellulose membranes 
by using a semi-dry electroblotting system (iBlot™ Gel Transfer Device, Invitrogen). 
Membranes were blocked in 5% non-fat milk in Tris-buffered saline containing 0.1% 
Tween-20 (TTBS) for 1 h. After blocking, membranes were incubated overnight at 4ºC 
with primary antibodies (diluted in 1% bovine serum albumin in TTBS, all purchased 
from Cell Signaling, Danvers, MA, USA, unless noted otherwise) against various target 
proteins as follows (Table 2): the main effector of NO signaling, PKG (Enzo Life 
Sciences, Plymouth Meeting, PA, USA), and its targets such as vasodilator-stimulated 
phosphoprotein (VASP) and Pln, as well as phospho-VASP (p-VASP) and phospho-Pln 
(p-Pln). After washing, membranes were incubated in horseradish peroxidase (HRP) –
conjugated secondary antibody dilutions at room temperature for 1 h (anti-rabbit IgG or 
anti-mouse IgG as appropriate, 1:2000). Immunoblots were developed using Pierce® 
ECL Western Blotting Substrate Kit (Thermo Scientific). Protein band densities were 




 (primary antibody purchased from Millipore, Billerica, MA, USA) was used to assess 
equal protein loading. Values of protein band densities (after adjusting to GAPDH band 
densities) were normalized to the average value of the ShamCo group and were used to 
perform statistical analysis. Representative original immunoblots are shown in Figure 
20. 
4.9. Drugs 
All drugs listed were purchased from Sigma-Aldrich (St. Louis, MO, USA) except for 
cinaciguat, which is a kind gift of Bayer AG (Leverkusen, Germany). 
4.10. Statistical Analysis 
Statistical analysis was performed on a personal computer with commercially available 
software (GraphPad Prism 7, La Jolla, CA, USA). All data are expressed as mean ± 
standard error of the mean. After testing normal distribution of the data using the 
Shapiro-Wilk test, Student’s t-testing or two-factorial analysis of variance (ANOVA, 
Table 2. Antibodies used for immunoblot analysis 







GAPDH MAB374 (Millipore, Billerica, MA, USA) 1:10000 38 kDa 
phospholamban Pln 8495 (Cell Signaling, Danvers, MA, USA) 1:5000 24 kDa 
phospho-Pln p-Pln 8496 (Cell Signaling) 1:5000 24 kDa 
phospho-VASP p-VASP 3114 (Cell Signaling) 1:500 50 kDa 
protein kinase G PKG 
ADI-KAP-PK005-F 
(Enzo Life Sciences, 
Plymouth Meeting, PA, 
USA) 




VASP 3112 (Cell Signaling) 1:1000 50 kDa 
The table shows the primary antibodies used against various protein targets and 





with ’aortic banding’ and ’cinaciguat treatment’ as factors) was carried out as 
appropriate. The two-factorial ANOVA was used to detect independent effects of the 
factors (pband, ptreat) and significant banding×treatment interactions (pint). Tukey’s post 
hoc testing was performed to evaluate differences between the groups. Data that did not 
show normal distribution were transformed logarithmically before performing two-
factorial ANOVA in order to reach normal distribution. A paired Student’s t-test was 
performed for comparing data of the echocardiographic measurements at 2 time points 
within a group. Furthermore, to test for the effect of the different hypertrophic stimuli in 
the models used (pdiff), a two-tailed Student’s t-test was performed using Ex and AAB 
values that were normalized to their respective controls. Differences were considered 





5. Results  
5.1. Differences between physiological and pathological myocardial hypertrophy 
5.1.1. Morphological assessment 
Heart weight in both Ex and AAB animals increased significantly compared with their 
respective controls (Table 3.). Normalization to tibia length revealed that although the 
difference in body weight might mask the difference in relative heart weight between 
the models, the increase in heart weight was more pronounced in the AAB group than in 
Ex animals (Table 3.). 
5.1.2. Echocardiographic parameters 
Heart rate was comparable among the groups. Anterior and posterior wall thickness was 
increased in both hypertrophy models both in systole and diastole (Table 4.). Estimated 
LVM and LVMi was also increased in Ex and AAB rats compared with their respective 
controls. Diastolic LV chamber size was similar in the two models, while end-systolic 
diameter significantly decreased in the Ex group, resulting in significantly increased EF 
and FS in these animals (Table 4.). A differential effect of the hypertrophic stimulus on 
phenotypic changes was observed in LVESD, LVM, FS and EF (Table 4.). 
Table 3. Exercise and pathological stimuli result in similar degree of 
hypertrophy 
 Sed Ex Sham AAB pdiff 
HW (g) 1.32±0.03 1.46±0.03* 1.29±0.03 1.61±0.06# 0.011 
BW (g) 469±10 402±10* 421±14 435±16 <0.001 
HW/BW (mg/g) 2.85±0.06 3.64±0.10* 3.07±0.10 3.69±0.10# 0.112 
HW/TL (mg/mm) 30.0±0.8 33.5±1.0* 29.3±0.7 37.3±1.2# 0.017 
AAB: abdominal aortic banding; Ex: exercised; Sed: sedentary; Sham: sham operated; 
HW: heart weight; /BW: normalization to body weight; /TL: normalization to tibia length; 
pdiff: p value of the difference between the models 




5.1.3. Pressure-volume analysis 
The baseline hemodynamic characteristics of physiological and pathological 
hypertrophy are summarized in Table 5. Ex rats displayed decreased LVESV compared 
with the sedentary animals, which accompanied by unchanged HR and LVEDV, 
resulted in increased SV, EF, CO and SW (Table 5.). LV pressures, dP/dtmax and 
dP/dtmin were unaltered, while Ea decreased in our exercised rats. In contrast, LV 
volumes and thus SV,  
Table 4. Exercise and pathological stimuli result in similar degree of 
hypertrophy – echocardiographic measurements 
 Sed Ex Sham AAB pdiff 
HR 
(beats/min) 357±15 351±10 378±24 382±11 0.500 
LVEDD (mm) 6.85±0.05 6.89±0.03 6.79±0.08 6.95±0.08 0.532 
LVESD (mm) 4.06±0.08 3.45±0.09* 3.99±0.17 4.22±0.11 <0.0001 
AWTd (mm) 1.96±0.02 2.17±0.02* 1.95±0.02 2.19±0.03# 0.452 
AWTs (mm) 3.02±0.05 3.37±0.06* 2.94±0.10 3.32±0.07# 0.731 
PWTd (mm) 1.82±0.03 1.93±0.02* 1.78±0.01 2.06±0.04# 0.002 
PWTs (mm) 2.91±0.04 3.09±0.04* 2.84±0.06 3.09±0.04# 0.356 
LVM (mg) 872±14 976±11* 849±17 1031±23# 0.012 
LVMi 
(mg/mm) 20.2±0.4 24.6±0.3
* 20.2±0.3 26.0±0.7# 0.264 
FS (%) 41.4±0.7 50.0±1.1* 41.3±2.3 40.5±1.3 <0.0001 
EF (%) 65.5±1.3 73.0±1.3* 65.1±1.5 62.4±1.3 <0.0001 
AAB: abdominal aortic banding; Ex: exercised; Sed: sedentary; Sham: sham operated; 
HR: heart rate; LVEDD: LV end-diastolic diameter; LVESD: LV end-systolic diameter; 
AWTd/s: anterior wall thickness in diastole/systole; PWTd/s: posterior wall thickness in 
diastole/systole; LVM: left ventricular mass; LVMi: LVM index (LVM normalized to 
tibia length); FS: fractional shortening; EF: ejection fraction; pdiff: p value of the 
difference between the models 




Table 5. Hemodynamic characteristics of physiological and pathological 
myocardial hypertrophy 
 Sed Ex Sham AAB pdiff 
HR (beats/min) 412±9 400±8 429±15 434±11 0.378 
MAP (mmHg) 145.3±2.8 142.1±5.2 142.0±2.0 182.3±7.9# 0.001 
LVEDP (mmHg) 3.0±0.2 3.7±0.4 3.9±0.7 4.4±0.4 0.131 
LVESP (mmHg) 154.8±3.4 152.2±8.2 150.8±2.0 213.4±6.8# <0.0001 
dP/dtmax (mmHg/s) 9237±397 9847±659 9103±424 12185±399# 0.012 
dP/dtmin (mmHg/s) -12191±443 -12213±670 -12390±261 -12506±676 0.780 
τ (ms) 12.1±0.3 11.2±0.3* 11.7±0.6 16.6±1.3# 0.001 
EDPVR (mmHg/µl) 0.036±0.003 0.042±0.003 0.034±0.004 0.042±0.006 0.680 
LVEDV (µl) 234±5 239±6 240±7 262±9 0.239 
LVESV (µl) 112±2 99±2* 106±5 114±5 0.002 
SV (µl) 123±6 141±5* 134±7 147±6 0.247 
EF (%) 52±1 58±1* 56±2 56±1 0.001 
CO (ml/min) 50.6±2.0 56.2±1.5* 58.5±3.9 63.7±2.8 0.263 
SW (mmHg*ml) 14.7±0.8 18.0±0.8* 15.6±1.2 22.7±1.2# 0.046 
PVA (mmHg*ml) 25.6±1.6 25.4±1.8 26.8±1.6 37.3±3.9# 0.017 
Ea (mmHg/µl) 1.33±0.05 1.09±0.08* 1.07±0.05 1.48±0.07# <0.0001 
Eff (%) 58±3 71±3* 58±3 63±4 0.173 
VAC 0.53±0.03 0.32±0.03* 0.42±0.02 0.37±0.03 0.006 
AAB: abdominal aortic banding; Ex: exercised; Sed: sedentary; Sham: sham operated; HR: heart rate; MAP: mean 
arterial pressure; LVEDP: LV end-diastolic pressure; LVESP: LV end-systolic pressure; dP/dtmax: maximal 
increment of pressure change; dP/dtmin: maximal decrement of pressure change; τ: time constant of active LV 
relaxation; LVEDV: LV end-diastolic volume; LVESV: LV end-systolic volume; SV: stroke volume; EF: ejection 
fraction; CO: cardiac output; CI: cardiac index (CO normalized to body weight); SW: stroke work; PVA: pressure-
volume area; Ea: arterial elastance; Eff: mechanical efficiency; VAC: ventriculo-arterial coupling; pdiff: p value of 
the difference between the models 




EF and CO did not change significantly in the AAB animals compared with Sham rats. 
In this model, however, LVESP and, consequently, MAP significantly increased in the 
AAB group, leading to increased values of dP/dtmax, SW and Ea (Table 5.). 
Representative PV loops and vena cava occlusions from all groups are shown in Figure 
11. Load-independent indices of systolic cardiac function calculated from occlusions 
(Ees, PRSW and dP/dtmax-EDV) all showed increased contractility in both hypertrophy 
models (Figure 11.). With respect to diastolic function, τ was significantly decreased in 
the Ex group compared with Sed animals, while it was significantly increased in the 
AAB rats compared with the Sham group (Table 5.). 
Cardiac mechanoenergetics were also differentially influenced by the two types of 
hypertrophic stimuli. SW was elevated in both physiological and pathological 
hypertrophies, although it was increased significantly more following AAB than 
exercise (Table 5.). Furthermore, mechanical efficiency (Eff) was significantly better 
following exercise, while remained unchanged after AAB (Table 5.). Compared with 
their respective controls, ventriculo-arterial coupling (VAC) was also improved in the 
Ex group, while it was mitigated in the AAB animals (Table 5.). 
5.1.4. Histology 
Cardiac hypertrophy was observed on the microscopic level as well (Figure 12. A, C): 
average cardiomyocyte diameter was increased in both hypertrophy models. In contrast, 
while myocardial collagen content did not increase in physiological hypertrophy, 
pathological hypertrophy was characterized by a significant increase of subendocardial 
collagen deposition (Figure 12. B, C). 
5.1.5. Cardiac mRNA analysis 
Physical exercise did not result in significant changes regarding cardiac gene expression 
(Figures 13. and 14.). In contrast, mRNA expression of genes involved in reactivation 
of the fetal gene program, such as ANP, MHCα and MHCβ (Figure 13. A), or 
expression of effectors important in mitochondrial function, such as CytC, Nrf1 and 
PGC1α (Figure 14.) was altered following pressure overload of the LV. Investigated 
markers of antioxidant defense and inflammatory processes were found to be unchanged 









































































































































































































































































































































































































































































































































































































































Figure 13. Elements of the fetal gene program are reactivated in pathological, but not in 
physiological hypertrophy, while expression of antioxidants and inflammatory markers 
are left unchanged in both hypertrophy models 
A characteristic alteration under pathologic conditions is the reactivation of the fetal gene program, 
a prominent marker of which is the myosin heavy chain isoform switch (A). A significant increase in 
LV wall stretch in the AAB group was confirmed by the elevation of ANP expression (A). No 
significant alterations were observed in antioxidant (B) or inflammatory (C) markers among the 
groups. Neither of these changes was present in physiological hypertrophy (A-C). 
ANP: atrial natriuretic peptide; Cat: catalase; IL-1β: interleukin 1β; MHCα/β: myosin heavy chain 
α/β; SOD-2: superoxide dismutase 2; TGFβ: transforming growth factor β; TNFα: tumor necrosis 
factor α; Trx1: thioredoxin 1. 
*: p<0.05 vs. Sed; #: p<0.05 vs. Sham 
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Figure 14. Myocardial mRNA expression of markers involved in metabolic processes are 
changed in pathological, but not in physiological hypertrophy 
Several markers of mitochondrial function were found to be significantly less expressed in 
myocardial samples of the AAB group than that of the Sham animals, suggesting a pathological shift 
of energy source from fatty acids to glucose in the AAB group. Neither of these changes was present 
in physiological hypertrophy. 
CytC: cytochrome C; Errα: estrogen-related receptor α; Nrf1: nuclear respiratory factor 1; PGC1α: 
peroxisome proliferator activated receptor γ coactivator 1α; PPARα: peroxisome proliferator 
activated receptor α. 
*: p<0.05 vs. Sed; #: p<0.05 vs. Sham 
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5.2. Effects of cinaciguat in pathological myocardial hypertrophy 
5.2.1. Morphological assessment 
There was no significant difference among the groups in body weight (Table 6.). Heart 
weight normalized to tibia length (HW/TL) was significantly higher in the AABCo rats 
than in the ShamCo or ShamCin animals (Table 6.). HW/TL was significantly reduced 
in the AABCin animals compared with the AABCo rats. Relative lung weight 
(LuW/TL) was significantly increased in the AABCo group compared with ShamCo. 
This parameter did not differ from ShamCo in the AABCin animals (Table 6.). 
5.2.2. Echocardiographic parameters 
The echocardiographic measurement performed on the 3rd postoperative week verified 
significantly elevated LV wall thickness values, RWT and estimated LVM in the 
AABCo group compared with ShamCo without significant changes in chamber 
dimensions (Figure 15. A). LVH increased over the second half of the treatment period 
in the AABCo animals (Figures 15. and 16.), which was accompanied by significantly 
elevated LVESD compared with ShamCo. Treatment with cinaciguat in aortic banded 
rats resulted in significantly decreased LV diastolic wall thicknesses, LVM and LVM 
index (LVMi) compared with AABCo at both time points (Figure 15. A). Systolic 
posterior wall thickness at the 6th week of the treatment was also significantly decreased 
in the AABCin animals compared with the AABCo group, while EF and FS remained 
unchanged during the whole study (Figure 15. B). 
5.2.3. Invasive hemodynamic measurements and P-V analysis 
Basic hemodynamic parameters, such as HR, EF, SV, CO, or LVESV, and also 
parameters of preload, such as LVEDV and LVEDP were not significantly different 
among the groups (Table 7.). 
LVESP and mean arterial pressure (MAP) proximal to the site of stenosis were 
significantly higher in both AAB groups than in the Sham groups, and neither of these 
parameters was affected by Cinaciguat (Table 7.). dP/dtmax was significantly higher in 

































































































































































































































































































































































































































































































































































































 Figure 15. Cinaciguat significantly decreases the extent of myocardial hypertrophy 
induced by pressure overload 
A: wall thickness and LV mass continuously increased in pressure overload during the six-week 
protocol. The cinaciguat treatment significantly decreased the thickening of LV walls and, 
consequently, ameliorated the increase in LVM at both time points. 
B: chamber dimensions did not change dramatically during the study period. Accordingly, 
relative wall thickness systolic parameters, such as EF or FS also remained unchanged. 
AWTd/s: anterior wall thickness in diastole/systole; PWTd/s: posterior wall thickness in 
diastole/systole; LVM: left ventricular mass; LVMi: LVM index; LVEDD: LV end-diastolic diameter; 
LVESD: LV end-systolic diameter; EF: ejection fraction; FS: fractional shortening; RWT: relative 
wall thickness. 
*: p<0.05 vs. ShamCo; #: p<0.05 vs. AABCo; $: p<0.05 vs. 3rd week 
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Load independent indices of contractility, such as Ees and PRSW (Figure 17. B), also 
showed that AABCo animals had significantly elevated LV contractility compared with 
ShamCo. These parameters, however, indicated a significant decrease of contractility in 
AABCin compared with AABCo rats. dP/dtmax-EDV had a similar trend (Figure 17. B). 
Active relaxation was impaired in the AABCo rats compared with ShamCo, as 
evidenced by τ, while it was similar to ShamCo in the AABCin animals (Table 7.). 
Figure 16. Representative echocardiographic images from the 6th week in diastole 
White bars represent walls, and red bars show cavities. Note the difference among groups in 

































































































































































































































































































































































































































































































































































































































































































































































































































Figure 17. Cinaciguat normalises increased contractility in pressure overload 
Baseline characteristics of pressure-volume relations did not differ in the AABCo and AABCin groups 
(A, top row). PV loops recorded during occlusion of the inferior vena cava (A, bottom row) and the 
load independent indices of contractility derived from these measurements (B) show, however, that 
cinaciguat significantly decreased the increase in contractility following abdominal aortic banding. 
Ees: end systolic elastance; PRSW: preload recruitable stroke work; dP/dtmax-EDV: maximum rate of 
pressure change – end diastolic volume relationship; pint: interaction p value 




Morphological changes were present on the microscopic level as well. Average 
cardiomyocyte width was significantly increased in the AABCo group compared with 
ShamCo (Figure 18. A, E), and was significantly lower in AABCin rats than in AABCo 
animals. Quantitative analysis of heart sections stained with Picrosirius red showed that 
the collagen area of subendocardial LV myocardium was significantly increased in the 
AABCo group compared with ShamCo, which was significantly decreased in the 
AABCin rats compared with AABCo (Figure 18. B, F). TUNEL staining revealed a 
significant increase in DNA fragmentation, which implies an increase in the number of 
possibly apoptotic cell nuclei in the AABCo group compared with ShamCo and 
AABCin (Figure 18. C, G). 
Analyzing immunohistochemical staining on myocardial sections for cGMP resulted in 
significantly higher score in AABCin rats than either in ShamCo or AABCo animals 
(Figure 18. D, H). 
5.2.5. Molecular and biochemical measurements 
5.2.5.1. Cardiac mRNA analysis 
Pressure overload of the left ventricle resulted in elevated myocardial expression of 
ANP and NOS3 (Figure 19. A) as well as decreased ratio of MHCα/MHCβ expression 
(Figure 19. A), indicating the reactivation of the fetal gene program in the AABCo 
animals. Treatment with cinaciguat normalized the relative expression of NOS3 and the 
ratio of MHCα/MHCβ expression (Figure 19. A), while ANP expression was unaltered 
by the treatment (Figure 19. A). Expression ratio of SERCA2a and Pln was significantly 
elevated in the AABCin rats (Figure 19. A). 
Anti-apoptotic signaling was reinforced by Cinaciguat, as evidenced by the significant 
increase in Bcl-2 expression and the strong tendency towards higher expression of 
HSP70 in the AABCin animals (Figure 19. B). 
5.2.5.2. Plasma cGMP measurement 
Plasma level of cGMP was significantly elevated in the AABCin animals compared 











































































































































































































































































































































































































































  Figure 19. Cinaciguat treatment favourably alters gene expression profile in 
pressure overloaded hearts  
A: Aortic banding resulted in reactivation of the foetal gene program, as evidenced by 
elevated expression of ANP, MHCβ, and NOS3, as well as the decreased expression of 
MHCα. Expression of NOS3 and MHCα along with the MHC isoform expression ratio was 
normalised by the cinaciguat treatment following aortic banding. The SERCA2a/Pln 
expression ratio was significantly increased in the AABCin rats compared with the AABCo 
animals. 
B: both HSP70 and Bcl-2 expression was markedly elevated in the AABCin group, 
indicating reinforced anti-apoptotic signalling in these animals. 
ANP: atrial natriuretic peptide; Bcl-2: B-cell lymphoma 2; HSP70: 70 kDa heat shock 
protein; MHCα/β: α and β isoform of myosin heavy chain; NOS3: endothelial nitric oxide 
synthase; Pln: phospholamban; SERCA2a: sarcoplasmic and endoplasmic reticulum Ca2+ 
ATPase isoform 2a; pint: interaction p value 





5.2.5.3. Immunoblot analysis 
Protein density of PKG was significantly elevated in myocardial homogenates of 
AABCo rats, while it was comparable to ShamCo in the AABCin group (Figure 20.). 
Phosphorylation ratio of VASP and Pln are widely used indicators of PKG activity, both 
of which were elevated following cinaciguat treatment (Figure 20.). Representative 
images showing original blots are displayed in Figure 21. 
  Figure 20. Effects of Cinaciguat on cGMP signalling in pressure overload 
The strong sGC activating effect of Cinaciguat during pathologic conditions was confirmed 
by measuring plasma level of cGMP, which was significantly elevated in AABCin rats. 
cGMP activates PKG, which then phosphorylates VASP and Pln, phosphorylation ratio of 
which are widely used markers of PKG activity. Both of these were markedly increased 
despite the unchanged amount of PKG in the AABCin group, indicating increased PKG 
activity in these animals. Representative Western blot bands are shown for each group and 
investigated protein on the right. 
PKG: protein kinase G; Pln: phospholamban; VASP: vasodilator stimulated 
phosphoprotein; pint: interaction p value 




Figure 21. Representative immunoblots showing antibody specificity 
The last ShamCo band on every blot was used to normalize differences in 
chemiluminescence between blots incubated with the same antibody. 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase; PKG: protein kinase G; Pln: 





6.1. Differences between physiological and pathological myocardial hypertrophy 
We gave direct hemodynamic comparison of physiological and pathological LVH in 
this study for the first time using a pressure-conductance catheter system in relevant 
small animal models. Characteristics of energy-dependent LV performance in these 
models were found to be distinctly different despite the comparable degree of LVH. 
According to our data, a possible underlying mechanism might be the alteration of 
mitochondrial regulation, appearing in the form of differential myocardial expression of 
mitochondrial markers. 
Cardiac hypertrophy is described as the response of the heart to a variety of stimuli that 
impose increased biomechanical stress on it. The hypertrophic phenotype is 
characterized by an increase in cardiomyocyte size, enhanced protein synthesis, and a 
better organization of the sarcomere (Frey & Olson, 2003). In line with these 
observations, both chronic pressure overload and exercise training led to significantly 
increased heart weight (Table 3.) and LV wall thickness values (Table 4.) in rats. LV 
mass index data revealed that the extent of LV mass increase compared with control is 
~20–25% after exercise training and ~25–30% after the stimulus of chronic pressure 
overload (Table 4.). These results are comparable with the findings of our previous 
study (Oláh et al., 2015) and other experimental investigations (McMullen et al., 2003; 
Wang et al., 2010; Wilkins et al., 2004). Histological evaluation of average LV 
cardiomyocyte diameter on H&E-stained sections confirmed comparable hypertrophy of 
cardiomyocytes in both Ex and AAB animals (Figure 12.), providing further evidence 
for a corresponding LVH in our models. Despite the similar extent of LV mass increase, 
there is a major difference between physiological and pathological hypertrophy. While 
regular exercise did not induce collagen deposition, pressure overload resulted in 
subendocardial accumulation of collagen (Figure 12.), which is in line with previous 
results with AAB (Derumeaux et al., 2002). Interestingly, despite excess collagen was 
deposited in the LV of our AAB animals, TGF-β expression was left unchanged after 6 
weeks of pressure overload (Figure 13. C). This discrepancy, however, might be 
explained by previous findings regarding attenuation of the initial surge of TGF-β 
expression during sustained pressure overload (Li & Brooks, 1997). The absence of 
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fibrotic remodeling in our Ex animals provides further evidence for the physiological 
nature of LVH after long-term exercise training (Wilkins et al., 2004). On the molecular 
level, reactivation of the fetal gene program in the heart is a hallmark of pathological 
hypertrophy (Frey & Olson, 2003), during which, as a major change, a shift from the 
normal expression of the α isoform of myosin heavy chain toward the less efficient, but 
less energy consuming β isoform occurs. Such alterations in the gene expression profile 
are not present in exercise training-induced LV enlargement (Figure 13. A). In line with 
this, altered myocardial expression of markers of this gene program, such as MHCα, 
MHCβ and ANP clearly demonstrated the pathological nature of LVH following AAB 
(Figure 13. A), while the absence of these changes after 12 weeks of training (Figure 13. 
A) supports our observation of physiological LVH in Ex animals (Iemitsu et al., 2001;
McMullen et al., 2003). 
The transition of pathological hypertrophy to overt heart failure is associated with 
myocardial oxidative stress and activated inflammatory processes (Bernardo et al., 
2010). Intensive oxidative stress and the consecutive inflammatory response, however, 
might not play a significant role in our 6-week long model of pathological hypertrophy, 
which is evidenced by unaltered myocardial expression of endogenous antioxidants and 
inflammatory cytokines (Figure 13. B, C). These results support the notion of the 
observed pathological hypertrophy being compensated in nature, and are in line with 
results comparing compensated myocardial hypertrophy with the failing heart in a 
model of pressure overload (Brooks et al., 2010). We did not expect nor found any 
alterations in the expression of oxidative stress- and inflammation-related markers in 
exercise-induced hypertrophy, which is in alignment with literature data [Figure 13. B, 
C, (Iemitsu et al., 2001)]. 
Exercise did not influence pressure conditions within the LV (Table 5.). Concerning 
volume relations, contrary to what is observed in human athletes – i.e., physiological 
hypertrophy induced by aerobic training is associated with increased end-diastolic 
volume and decreased heart rate compared with sedentary individuals (Maron, 1986) –, 
our exercised animals under anesthesia displayed unaltered end-diastolic, but smaller 
end-systolic dimensions together with similar heart rate compared with control rats 
(Figure 11. A and Table 4.). Heart rate, although might be expected to show a decrease 
in exercised rats, was found similar among the groups (Table 3.). This finding was most 
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probably the consequence of all functional measurements being completed on animals 
under appropriate anesthesia, which affects the vegetative nervous system significantly 
enough to dampen the potential differences in this parameter observable in awake 
animals. These changes in baseline hemodynamics, however, led to a net increase in 
stroke volume, cardiac output, ejection fraction and fractional shortening in our 
exercised rats, similarly to what is characteristic to athlete’s heart, as shown in human 
studies using noninvasive methods (Scharhag et al., 2002; Spirito et al., 1994), 
excluding ejection fraction that is unchanged or may even be decreased at rest in 
humans (Prior & La Gerche, 2012). The increase in ejection fraction observed in our Ex 
rats, an alteration that does not correlate with what is characteristic to human athlete’s 
heart, is most probably the consequence of the enormous difference in resting heart rate 
between humans and rats. The heart rate of rats is 6-8-fold higher than that of humans, 
which shortens the time available for diastole at rest to an extent that significantly 
increasing diastolic volume is unachievable. Therefore, the rat heart adapts to exercise 
by increasing contractility (Figure 11.) and ejection fraction (Tables 4. and 5.), the latter 
through decreasing end-systolic volume (Table 5.). 
Abdominal aortic banding, on the other hand, was associated with a marked increase in 
MAP (~40 mmHg), peak LV systolic pressure (~60 mmHg) and unchanged LV end-
diastolic pressure, while LV volumes were only slightly shifted toward higher values – 
leading to relatively unchanged stroke volume, cardiac output, fractional shortening and 
ejection fraction –, a phenomenon corresponding to results from other groups 
investigating pressure overload-induced cardiac hypertrophy [Figure 15. B and Table 7., 
(Derumeaux et al., 2002; Moens et al., 2008)]. Furthermore, these data confirm the lack 
of chamber dilatation in AAB rats, also corresponding to experiments using abdominal 
aortic banding (Figure 15. B) (Derumeaux et al., 2002; Juric et al., 2007). The extent of 
hypertension in our animals is comparable with the findings of other studies using this 
method to induce pathological hypertrophy in rodents (Kompa et al., 2010; McMullen 
et al., 2003). These data imply preserved systolic function, which altogether suggest 
that our animals were in the compensated phase of pathological hypertrophy after 6 
weeks of pressure overload. 
In summary, concerning baseline LV P-V relations, physiological hypertrophy is 




output, while the pathological stimulus-induced hypertrophy presents itself mainly as – 
a pathological – adaptation to increased systolic pressure with relatively unaltered 
volume conditions. Furthermore, conventional parameters describing systolic function, 
such as ejection fraction and fractional shortening, are increased in physiological, while, 
at the stage we investigated, maintained in pathological hypertrophy, clearly reflecting 
the difference between the underlying stimuli. 
LV contractility is traditionally approximated using the peak rate of systolic pressure 
increment, dP/dtmax. This parameter, however, is influenced mainly by preload, but heart 
rate or extremely increased afterload also deteriorates its value (Cingolani & Kass, 
2011). As such, this parameter might be especially unreliable in our AAB rats. Pressure-
volume analysis provides precise and reliable parameters of LV contractility utilizing 
the P-V relations recorded during occlusion of the inferior vena cava, a transient preload 
reduction maneuver. Thus, load-independent indicators of ventricular contractility can 
be calculated. The most widely used such sensitive contractility index, Ees was 
significantly increased in both swim-trained and AAB rats (Figure 11. A, B). Preload 
dependence of stroke work and dP/dtmax, both being load-dependent indices, can 
effectively be reduced by using linear regression to end-diastolic volume when 
measured during the preload-reducing maneuver (Cingolani & Kass, 2011). The 
resulting load-independent indices, PRSW and dP/dtmax-EDV were also increased in 
both hypertrophy models, confirming the increase in contractility in both exercise 
training- and pressure overload-induced LVH. These observations are in line with our 
previous results in physiological hypertrophy (Radovits et al., 2013) and with formerly 
published data of pressure overload-induced pathological hypertrophy in rodents (Chen 
et al., 2013; Takimoto et al., 2005b). Control animals of our models showed similar 
contractility (Figure 11. A, B). 
Ventricular diastole comprises two main phases: active relaxation followed by passive 
filling. The first phase of diastole, LV relaxation is considered an active, energy-
consuming process and depends mostly on Ca2+ reuptake by the sarcoplasmic reticulum 
during early diastole (Zhao et al., 2008). dP/dtmin was unchanged in both types of LVH, 
but the utility of this parameter under conditions that differ from physiological – much 
like dP/dtmax – is very limited due to its dependence on various hemodynamic factors, 
mostly loading conditions (Garrido et al., 1993). Again, P-V analysis provided a more 
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reliable index, τ, which has been described as a relatively load-independent index of 
active relaxation of the LV (Zhao et al., 2008). τ was decreased in physiological 
hypertrophy, which suggests a shorter isovolumetric relaxation period and thus 
enhanced relaxation in our trained rats (Table 5.). This is in line with previously 
published data from our workgroup in this model of athlete’s heart (Radovits et al., 
2013). In contrast, we observed a markedly lengthened relaxation in pathological 
hypertrophy (Table 5.). This is in accordance with investigations aiming at functional 
characterization of LVH induced by pressure overload; these studies utilized animal 
models including aortic constriction (Kompa et al., 2010; Takimoto et al., 2005b) or 
spontaneously hypertensive rats (Cingolani & Kass, 2011), and have yielded similar 
results regarding active relaxation. This discrepancy in active relaxation might be the 
most characteristic difference between the two types of investigated cardiac 
hypertrophies (Figure 12. B, C and Table 5.). Our findings are consistent with recent 
human echocardiographic studies, where hypertrophic cardiomyopathy and athlete’s 
heart could be distinguished by early diastolic components (Caselli et al., 2014; Kovacs 
et al., 2014). 
Passive filling during diastole is mainly defined by ventricular compliance. Although 
ventricular compliance is influenced by multiple factors, it is affected predominantly by 
alterations in myocardial intracellular and extracellular structural components [e.g., 
fibrosis or edema, (Pacher et al., 2008)]. The passive viscoelastic property – or stiffness 
– of the myocardium can be quantified by examination of the relationship between 
diastolic pressure and volume (Zile & Brutsaert, 2002a). Our protocols did not result in 
any significant alteration in EDPVR, and there was no difference between the 
hypertrophy models (Figure 11. A). These data are in good agreement with the lack of 
collagen deposition observed in the hearts of exercised animals (Figure 12. B, C). 
Furthermore, the slight increase of subendocardial fibrosis in AAB rats might not be 
extensive enough to result in characteristic functional consequences (Figure 12. B, C). 
LVEDP, another index of LV stiffness, was consistent with our observation concerning 
EDPVR, providing further support to the notion of unchanged LV stiffness in these 
models (Table 5.). 
SW describes the effective external mechanical work of the LV in one cardiac cycle, 




exercise training and pressure overload resulted in increased mechanical work due to 
increased stroke volume and elevated systolic pressure values, respectively (Figure 11. 
A and Table 5.). SW increased significantly more in pressure overload compared with 
exercise training, clearly reflecting the severe hypertension in these animals (Table 5.). 
PVA is the area in the P-V plane that is bound by the end-systolic and end-diastolic P-V 
relationship lines and the systolic segment of the P-V loop (Figure 10). It serves as a 
reliable index of total mechanical work, and is directly proportional to myocardial 
oxygen consumption (Suga et al., 1981). While this parameter was similar in control 
animals and exercised rats with physiological hypertrophy, pressure overload and the 
resulting pathological hypertrophy was associated with a marked increase in PVA, 
suggesting markedly increased energy consumption of the LV myocardium compared 
with sham operated animals (Table 5.). Taking a closer look at these results revealed 
that a greater proportion of the total work of the LV (PVA) manifested as effective work 
(SW) in exercised animals than in pressure-overloaded rat hearts. Therefore, mechanical 
efficiency (Eff) of LV performance was better in animals with exercise training-induced 
hypertrophy than in any other group (Table 5.). In other words, and in good agreement 
with our expectations, while increased work was achieved through an adaptive increase 
in LV mass and improvement of efficiency in training-induced physiological 
hypertrophy, matching the need for increased work induced by extreme afterload was 
only sustainable through an excessive increase in contractile mass without any 
improvement of efficiency in pathological hypertrophy resulting from pressure 
overload. The observed differences in efficiency, however, most probably do not 
originate from the LV alone. Other components of the cardiovascular system, such as 
the compliance of the arterial system connected to the LV, might play a significant role 
as well. The interaction between the LV and the arterial system is described by another 
important factor of cardiac mechanoenergetics, ventricular-arterial coupling (VAC), 
which can be calculated as the ratio of arterial elastance (Ea) and Ees (Sunagawa et al., 
1983). Ea is an integrative index of afterload that includes, among others, peripheral 
vascular resistance, arterial compliance, and characteristic impedance of the vasculature, 
giving an overall characterization of the total resistance of the arterial system. 
Decreased Ea in exercised rats revealed a better compliance of the arteries in our 




overload, clearly reflecting the increased afterload in our pathological hypertrophy 
model originating from the banding on the abdominal aorta (Table 5.). As Ees is 
similarly increased in both hypertrophy models, it is evident that the difference in Ea is 
responsible for the difference in VAC between physiological and pathological 
hypertrophy (Table 5.). Therefore, improved VAC in exercise-trained animals is most 
probably attributable to decreased arterial impedance, while the value of VAC in 
pressure overload-induced pathological hypertrophy indicates that the increased arterial 
load is merely compensated by the increased systolic LV performance (Table 5.). These 
observations are in accordance with human investigations describing ventriculo-arterial 
relations in athletes and in patients with hypertension-induced LVH (Florescu et al., 
2010; Nitenberg et al., 2001). 
In addition to what I discussed above, there might be a difference in metabolic 
efficiency between physiological and pathological myocardial conditions: exercise 
training is associated with enhanced fatty acid and glucose oxidation, whereas 
pathological hypertrophy is related to a decrease in fatty acid oxidation and increase in 
glucose metabolism (Bernardo et al., 2010; Gibb &Hill, 2018). Some of the most 
important investigated cardiac functional parameters, such as active relaxation, SW or 
mechanical efficiency, have each been referred to as energy-dependent indices; intact 
mitochondrial function, therefore, is vital for efficient cardiac functioning. Thus, we 
examined the myocardial expression of the master regulator of myocardial energy 
metabolism, the mitochondrial transcriptional coactivator PGC1α, which regulates 
mitochondrial biogenesis and function (Finck & Kelly, 2007). In line with literature 
data (Rimbaud et al., 2009), PGC1α and some of its important downstream coactivators 
and targets (ERRα, NRF1, PPARα, and CytC) were downregulated in pathological 
hypertrophy, suggesting mitochondrial dysfunction and a shift from lipid to glucose 
utilization (Figure 14.). In contrast, physiological cardiac hypertrophy was shown to be 
associated with normal or enhanced mitochondrial biogenesis (Rimbaud et al., 2009). 
Our data is in accordance with previous findings – there was no significant upregulation 
of these genes in our swim training model of athlete’s heart (Figure 14.). This difference 
in metabolism between our cardiac hypertrophy models supports the concept that 
targeting regulator molecules of mitochondrial biogenesis and function might play an 
important role in the treatment of pathological hypertrophy. 
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6.2. Effects of cinaciguat in pathological myocardial hypertrophy 
In this project we demonstrated for the first time that the chronic activation of sGC by 
cinaciguat and the subsequent rise in cGMP levels efficiently reduce pressure overload-
induced pathologic myocardial hypertrophy in vivo despite the unchanged loading of the 
LV. In parallel with the significant morphological changes, functional alterations were 
normalized by the cinaciguat treatment following AAB. 
In vivo, the major drive in the background of the hypertrophic response of 
cardiomyocytes to chronically increased afterload is stretching of the cell membrane 
(Seymour et al., 2015; Zhang et al., 2013). Recently published in vitro studies have 
shown that cinaciguat has anti-hypertrophic effects in cultured neonatal rat 
cardiomyocytes (Irvine et al., 2012), suggesting that chronic activation of the NO-
cGMP-PKG pathway is capable of decreasing cardiomyocyte hypertrophy irrespective 
of the mechanical stress inflicted on cardiomyocytes by hemodynamic load. The 
significance of NO-cGMP-PKG signaling in this protective effect might be that it 
regulates a plethora of important mechanisms including Ca2+-related signaling 
pathways, as well as phosphorylation of troponin I (Kaye et al., 1999) and various ion 
channels (Bai et al., 2005). Our present results are in line with the above mentioned 
anti-hypertrophic properties of sGC-activation. In vivo myocardial anti-hypertrophic 
effect of cinaciguat in previously published works, however, was suggested to be 
secondary to amelioration of the primary disease [pulmonary hypertension (Dumitrascu 
et al., 2006) and uremia (Kalk et al., 2006)] by the drug. In contrast, banding on the 
abdominal aorta and thus the pathological stimulus in our model cannot be resolved by 
the drug, therefore we showed with this project for the first time that cinaciguat exerts a 
primary anti-hypertrophic effect in vivo, irrespective of the hemodynamic loading of the 
LV. The observed effect might be the result of increased activity of PKG brought about 
by the elevation of intracellular cGMP levels in response to cinaciguat. This conclusion 
is supported by myocardial and plasma cGMP-levels (Figures 18. D, H and 20.), and 
increased phosphorylation ratio of VASP and Pln (Figure 20.), both of which are widely 
used as markers of PKG activity (Gorbe et al., 2010; Sartoretto et al., 2009). 
Although oxidation and thus inactivation of sGC has been reported to contribute to the 
development of LVH (Tsai et al., 2012), plasma cGMP levels were found to be 




explained by the overexpression of natriuretic peptides (such as ANP, Figure 19. A) and 
subsequent cGMP-production by particulate GC (Kuhn, 2003) in our AABCo rats, and 
could be interpreted as an ineffective compensatory reaction to sGC inactivation. 
Furthermore, pGC seems to be improbable to directly replace the function of sGC in the 
cell; the different subcellular compartmentalization of sGC versus pGC derived cGMP 
should be taken into account (Castro et al., 2006). 
Similarly to the previous setting, significant concentric LVH was present in the AABCo 
group by the 6th week, as shown by RWT values. AWTd, PWTd and LVEDD were 
significantly decreased in the AABCin group compared with AABCo (Figure 15. A). 
Indeed, LVMi estimated from our echocardiographic measurements showed that 
cinaciguat significantly decreased the extent of LVH (Figure 15. A). Our finding 
correlates with data about the PDE-5 inhibitor sildenafil, which also increases the 
amount of intracellular cGMP, and was shown to reduce LVH significantly (Takimoto 
et al., 2005a). Post mortem organ weight measurements correlated with these results: 
AABCo rats developed a significant increase both in absolute and relative heart weight 
compared with ShamCo, which is similar to previous data in this model (Schunkert et 
al., 1990). The gain of heart weight was significantly decreased by cinaciguat treatment 
(Table 6.), which clearly reflects the anti-hypertrophic properties of the compound. 
Chronically increased afterload induces compensatory remodeling of the myocardium. 
Unlike physiological myocardial hypertrophy, as it has been described above, 
pathologic stimuli such as hypertension, lead to maladaptive changes in the cellular 
structure of cardiomyocytes (McMullen & Jennings, 2007). On the microscopic level, 
we found a significant increase in average cardiomyocyte width and subendocardial 
collagen area in the AABCo group compared with ShamCo (Figure 18. A, B, E, F), 
confirming our previous results (Figure 12. B, C). Treatment with cinaciguat 
significantly reduced both average cardiomyocyte width and subendocardial collagen 
area in our aortic banded rats (Figure 18. A, B, E, F), which correlates well with the 
decrease observed in LVMi and heart weight (Figure 14. A and Table 6.) both within 
this study and with previous results (Derumeaux et al., 2002; Takimoto et al., 2005a). 
A major change in the subcellular phenotype characteristic to pathologic LVH is the 
reactivation of the fetal gene program (Swynghedauw, 2006). Indeed, we observed the 
previously discussed characteristic switch in myosin heavy chain isotypes (Figure 19. 
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A) in AABCo animals, a well-known change (Izumo et al., 1987) that was completely
normalized by cinaciguat treatment, as observed in the AABCin group (Figure 19. A). 
This result is especially remarkable considering that loading of the LV was similar, as 
MAP was comparable in the aortic banding groups (Table 7.). It must again be noted 
here that cinaciguat has been critically discussed in a number of publications due to its 
hypotensive effect in human clinical trials utilizing the drug intravenously (Erdmann et 
al., 2013; Gheorghiade et al., 2012). It is very important to emphasize, however, that 
consistently with other pharmacological agents, pharmacokinetics of cinaciguat is 
significantly different when administered orally. In line with this, according to previous 
reports, a single oral dose of 10mg/kg cinaciguat only mildly and transiently lowers 
blood pressure (Stasch et al., 2002). Furthermore, chronic oral administration of the 
drug in this dose did not significantly alter arterial blood pressure in the systemic 
circulation neither in murine models of pulmonary hypertension (Dumitrascu et al., 
2006) nor in a rat model of diabetic cardiomyopathy (Matyas et al., 2015). Similar 
results with oral ataciguat and GSK2181236A, two further sGC activators have recently 
been reported in a rat myocardial infarction model and in spontaneously hypertensive 
stroke prone rats (Costell et al., 2012; Fraccarollo et al., 2014). Conforming to these 
data, we did not observe any changes in MAP of the rats in response to orally 
administered cinaciguat at the time of hemodynamic assessment, 24h after last 
application of the drug. Nevertheless, the observed robust overexpression of ANP in 
both AAB groups (Figure 18. A) provided evidence for unchanged loading, similar LV 
wall stretch and thus mechanical hypertrophic stimulus in the AABCo and AABCin 
animals. Similar results have been published regarding mTOR signaling (Boluyt et al., 
2004; Shioi et al., 2003), where a significant reduction in LVH was observed without 
any change in pressure overload; whether there is an interplay between cGMP and 
mTOR signaling, however, is yet to be elucidated. 
Excessive stretching of the plasma membrane of cardiac myocytes could also induce 
programmed cell death (Cheng et al., 1995). Our results correspond with previous data, 
because we observed a significant increase in DNA fragmentation, and thus in the 
number of possibly apoptotic cell nuclei in the AABCo group compared with ShamCo 
with TUNEL staining (Figure 18. C, G). This alteration was normalized by the 
cinaciguat treatment, which improvement could be explained by reinforced anti-
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apoptotic signaling, as evidenced by the increased expression of Bcl-2 and HSP70 
(Figure 19. B). 
Thus, we observed a significant improvement of the detrimental changes occurring 
during pathologic LVH on all three observable (i.e., macroscopic, microscopic and 
molecular) levels in response to cinaciguat treatment. 
As described above in more detail, chronic overload of the LV results in pathologic 
morphological changes of the myocardium, which initially result in a functionally 
compensated phase with hypertrophy and an increase in contractility, eventually leading 
to decompensation with LV dilatation, systolic dysfunction and overt HF (Litwin et al., 
1995). We found maintained systolic performance in our animals with 
echocardiography both on the 3rd and 6th week (Figure 15. B), which finding confirms 
our previous results in this model. The significantly increased LVESD in the AABCo 
animals, however, might anticipate LV dilatation and systolic dysfunction, while 
cinaciguat effectively prevented this alteration as well (Figure 15. B). 
Analysis of P-V data acquired during invasive hemodynamic measurements provides 
more precise assessment of cardiac performance. Ees was proposed as a fairly load-
insensitive index of ventricular contractility, while PRSW has been described to be a 
parameter independent of chamber size and mass in addition to load-insensitivity 
(Radovits et al., 2013). These indices showed an increase in LV contractility in the 
AABCo group, which was not present following cinaciguat treatment (Figure 17. B and 
Table 7.). These results are partially explained by the anti-hypertrophic effects of 
cinaciguat, as described above and in previous studies (Heineke & Molkentin, 2006; 
Takimoto et al., 2009). Further important contributors to these results might be 
functional changes induced by activation of PKG: inactivation of L-type Ca2+-channels 
and activation of late rectifier K+-channels by PKG might both decrease intracellular 
Ca2+ concentration (Bai et al., 2005). What is more, phosphorylation of troponin I by 
PKG could ameliorate Ca2+-sensitivity of cardiomyocytes (Kaye et al., 1999). 
Therefore, while not completely preventing adaptive compensatory hypertrophy 
(Figures 15. A, 16., 18. A, E and Table 6.), cinaciguat appears to attenuate the excess in 
hypertrophic response that might not be required for the LV to withstand increased 




of pathological hypertrophy including fibrosis (Figure 18. B, F), apoptosis (Figure 18. 
C, G) and reactivation of the fetal gene program (Figure 19. A). 
A hallmark of HHD is the impairment of LV diastolic function long before systolic 
dysfunction occurs, resulting clinically in the HFpEF phenotype. Both decrease of 
passive compliance and impaired active relaxation of the LV can be in the background 
of diastolic dysfunction (Zile & Brutsaert, 2002b). Conforming to our previous results 
discussed above, LVEDP did not change compared with ShamCo (Table 7.) despite the 
elevated subendocardial collagen area in the AABCo animals (Figure 18. B, F), which 
suggests that passive compliance of the LV was unaltered at this early stage of HHD. 
We confirmed in this study as well that increased collagen area was present only in the 
subendocardial region of the LV wall following 6 weeks of pressure overload, as shown 
on Picrosirius red stained sections (Figure 18. B). Collagen deposition, as observed by 
Derumeaux et al., expanded to the complete width of the LV wall when the duration of 
pressure overload was increased (Derumeaux et al., 2002). τ, on the other hand, which 
characterizes active relaxation, was significantly increased in the AABCo group, 
suggesting impaired active relaxation (Table 7.). There was no sign of diastolic 
dysfunction in the AABCin animals, which could be explained by the elevated ratio of 
expression of SERCA2a and Pln (Figure 18. A) and increased phosphorylation ratio of 
Pln (Figure 20.) compared with AABCo. Both of these changes could contribute to the 
facilitation of cytoplasmic Ca2+-clearance in the early phase of diastole, resulting in 
maintained active relaxation (del Monte et al., 1999; Tsuji et al., 2009), although further 
investigation is needed to elucidate the mechanisms underlying this phenomenon. 
Diastolic dysfunction causes backward failure initially in the pulmonary circulation 
(Lorell & Carabello, 2000). In accordance with this, we found significantly elevated 
relative lung weight in our AABCo rats, while it was comparable to ShamCo in the 




The most important and perhaps obvious limitation of these investigations is the use of 
small animals. The significant phylogenetic distance between humans and rats alone 
limits comparability, which is further aggravated by the vast difference in corporeal 
dimensions. Thus, all results discussed herein should be interpreted to human clinical 




Our current experiments provided the first detailed hemodynamic comparison of 
physiological and compensated pathological hypertrophy in relevant rodent models. 
Although the investigated types of myocardial hypertrophies were phenotypically 
similar, distinctive functional and molecular differences were present. Active relaxation 
during diastole was differentially affected: physiological hypertrophy was associated 
with a significant improvement, while pathological hypertrophy resulted in a significant 
deterioration. Furthermore, efficiency of the work of the LV and coupling to the arterial 
system was improved only in physiological hypertrophy. Altered myocardial expression 
of markers related to mitochondrial function and biogenesis, such as the master 
regulator PGC1α might explain the described energy-dependent functional differences. 
We showed for the first time in our second set of experiments that chronic activation of 
sGC by cinaciguat potently prevents the development of excessive myocardial 
hypertrophy induced by pressure overload in vivo. We observed this beneficial effect of 





With respect to its minimal proliferative capacity, the response of adult myocardium to 
increased load is hypertrophy. Depending on the factors leading to its development, this 
hypertrophic response varies significantly in either its molecular, morphological or 
functional characteristics. Based on these observations, physiological and pathological 
myocardial hypertrophy are traditionally distinguished, which, from a clinical point of 
view, differ most significantly in their prognosis. Thus, research on effective new 
pharmacological options inhibiting the development of pathological myocardial 
hypertrophy is of prime importance. 
Our aim with the current investigations was to discover functional, morphological and 
molecular differences between physiological and pathological myocardial hypertrophy 
in animal models, as well as to study the effects of pharmacological activation of the 
NO-cGMP signaling pathway, gaining prominence recently, in a rat model of 
pathological myocardial hypertrophy. 
We showed in our experiments that the most important difference between 
physiological and pathological myocardial hypertrophy at their early stage is found in 
diastolic function: while physiological hypertrophy is associated with a significant 
improvement, pathological hypertrophy leads to a marked deterioration of active 
relaxation compared with control. Changes in the metabolism of cardiomyocytes and 
energy production of their mitochondria might play an important role in the background 
of functional differences, while morphological alterations are not significant. 
We also revealed that pharmacological activation of the NO-cGMP signaling pathway 
effectively reduces extreme hypertrophic response of the myocardium to pressure 
overload, which includes reduction of futilely increased contractility and improvement 
of diastolic dysfunction, decrease of subendocardial collagen accumulation and DNA-
strand breaks in cardiomyocytes, as well as normalization of expression of 
pathologically reactivated genes characteristic to the fetal period of ontogeny. 
Based on our results we can conclude that the sGC activator cinaciguat might be an 
effective new therapeutic option in the prevention of pressure overload-induced 




A felnőtt szívizomzatot érő fokozott terhelés, tekintettel a miokardium minimális 
proliferációs képességére, hipertrófiás válasz kialakulásához vezet. A hipertrófia, 
függően a létrejöttéhez vezető okoktól, molekuláris, morfológiai és funkcionális 
szempontból is igen eltérő tulajdonságokkal rendelkezik. Ezek alapján tradicionálisan 
két nagy csoportot: fiziológiás, valamint patológiás miokardiális hipertrófiát különítünk 
el, melyek klinikai szemszögből legfontosabb különbsége a prognózisban rejlik, ezért a 
patológiás miokardiális hipertrófia kialakulását gátló új, hatékony gyógyszeres terápiák 
kutatása elsőrendű feladat. 
Jelen vizsgálatainkban célul tűztük ki, hogy a fiziológiás, valamint patológiás 
miokardiális hipertrófia állatmodelljein e két állapot funkcionális, morfológiai és 
molekuláris különbségeit feltárjuk, továbbá hogy a patológiás miokardiális hipertrófia 
patkánymodelljében a közelmúltban egyre nagyobb jelentőséget kapott NO-cGMP 
jelátvitel farmakológiai aktiválásának hatásait vizsgáljuk. 
Kísérleteink során igazoltuk, hogy a fiziológiás és patológiás miokardiális hipertrófia 
kezdeti szakaszában legfontosabb funkcionális különbség a diasztolé során jelentkezik: 
az aktív relaxáció fiziológiás hipertrófia esetén lényegesen javul, míg patológiás 
szívizom-megnagyobbodás alkalmával lényegesen romlik a kontrollhoz viszonyítva. 
Ennek hátterében a szívizomsejtek anyagcseréjében, illetve mitokondriumaik 
energiatermelésében beálló változások játszhatnak szerepet, miközben a morfológiai 
különbségek nem jelentősek. 
Kimutattuk továbbá, hogy a NO-cGMP jelátvitel gyógyszeres aktiválásával a 
nyomástúlterhelés hatására kialakuló szélsőséges hipertrófiás válasz mértéke 
hatékonyan csökkenthető. Ennek jeleként megfigyelhető volt a túlzott kontraktilitás 
csökkenése és a diasztolés diszfunkció mérséklése, a szubendokardiális kollagén 
mennyiségének, valamint a szívizomsejtekben megfigyelhető DNS-károsodás 
mértékének csökkenése, továbbá a magzati korra jellemző, kórosan újfent kifejeződő 
gének expressziójának normalizálódása. 
Eredményeink alapján kijelenthetjük, hogy a sGC aktivátor cinaciguat hatékony új 
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